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11. Abstract
1.1. Background
Tumors arising from the lung, pleura, or chest wall are a frequent problem in clinical
pulmonary medicine. Most lesions are either infectious, neoplastic or granulomatous in
nature, but a variety of other differential diagnoses must be considered. An accurate diagnosis
is important because the available treatments differ substantially, and because any delay will
impair the prognosis in potentially curable patients with lung carcinoma. The investigations
involve the disciplines of radiology, pulmonology, surgery, microbiology, and anatomical
pathology and consume a respectable amount of resources. The aim of the work covered in
this thesis was to optimize the available diagnostic methods for the routine use in a health
care setting with limited resources.
1.2. Methods
The general idea of this work was to identify conventional sampling methods that could be
developed further to become more useful for the diagnosis of chest tumors in a low resource
health care setting. The key method was research performed: a) to revise and expand the
indication for a sampling method, b) to technically improve the sampling process, and c) to
optimize sample transport, preparation and analysis in collaboration with the analytical
laboratory.
1.3. Results
A list of invasive diagnostic procedures, imaging methods and analytical processes were
developed, evaluated and integrated into clinical practice. A) transbronchial needle
aspiration, B) transthoracic cutting needle biopsy, C) transthoracic fine needle aspiration, D)
transthoracic ultrasound, and E) rapid on-site evaluation of needle aspirates by a
cytopathologist. Five studies pertaining to this thesis were published in international peer-
reviewed journals:
• Safety and yield of ultrasound-assisted transthoracic biopsy performed by
pulmonologists (Respiration 2004;71:519-22)
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2This paper established that ultrasound-assisted transthoracic biopsy performed by
pulmonologists is feasible, safe, practical, low-cost and has a high yield.
• Utility of rapid on-site evaluation of transbronchial needle aspirates (Respiration
2005;72:182-8)
This paper demonstrated the economical advantages of on-site evaluation of transbronchial
specimens in a low-resource setting.
• Transbronchial needle aspirates: comparison of two preparation methods (Chest
2005;127:2015-8)
This paper demonstrated that preparing smears on-site has a far better yield than pooling
samples into a vial. This means that the yield is improved over the current standard at no
additional cost.
• Transbronchial needle aspirates: how many passes per target site? (European
Respiratory Journal 2007;29:112-6)
This paper investigated the most economical and effective approach to serial sampling with
transbronchial needle aspiration during flexible bronchoscopy.
• Ultrasound assisted transthoracic biopsy: fine needle aspiration or cutting needle
biopsy? (European Respiratory Journal 2007;29:357-62)
This paper compared two common methods of sampling and demonstrates that the less
expensive method is sufficient in the majority of cases.
1.4. Conclusion
This work has impacted on current practice in multiple ways. Conventional methods have
been optimized by improving technical factors and with the integration of interdisciplinary
collaboration. The initiated research is ongoing with the aim to achieve continued technical
and economical improvements in the diagnosis of chest tumors.
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32. Abstrak
2.1. Agtergrond
Tumore van die long, pleura of borskaswand word gereeld geëvalueer in kliniese
pulmonolgie. Meeste letsels is infektief, neoplasties of granulomateus, maar heelwat ander
patologië moet oorweeg word in die differensiële diagnose. 'n Akkurate en spoedige diagnose
is belangrik, nie aanleenlik omdat die beskikbare hantering beduidend verskil nie, maar ook
omdat 'n vertraging die prognose van potensieël geneesbare long tumore kan verswak.
Spesiale ondersoeke betrek die dissiplines van Radiologie, Pulmonologie, Chirurgie,
Mikrobiologie en Anatomiese Patologie en is oor die algemeen duur. Die doel van die
navorsing wat die basis vorm van hierdie tesis was om die beskikbare diagnostiese tegnieke
te optimaliseer en aan te pas vir roetine gebruik in 'n gesondheidsisteem met beperkte
finansiële middele.
2.2. Metodes
Konvensionele metodes wat ingespan word tydens die verkryging van laboratorium monsters
is geïdentifiseer en geoptimaliseer met die doel om hierdie tegnieke meer bruikbaar te maak
in die diagnose van tumore van die toraks in 'n gesondheidsisteem met beperkte fondse.
Navorsing is gedoen: a) om die indikasies vir bepaalde metodes tydens die neem van
monsters te hersien en uit te brei, b) om die proses van monsterneming te optimaliseer, en c)
om die vervoer, voorbereiding en analise van monsters in samewerking met die betrokke
laboratoria te optimaliseer.
2.3. Uitslae
'n Lys van invasiewe diagnostiese prosedures, beeldings tegnieke en analitiese prosesse is
ontwikkel en geïntegreer in kliniese gebuik. A) transbrongiale naald aspirasie, B)
transtorakale snynaald biopsie, C) transtorakale fynnaald aspirasie, D) transtorakale
ultraklank, and E) spoedige in-teater evaluasie van naald aspirate deur sitopatoloë. Vyf
studies wat betrekking het tot hierdie tesis is gepubliseer in internasionale joernale:
• Safety and yield of ultrasound-assisted transthoracic biopsy performed by
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Hierdie studie het bevestig dat ultraklank-geassisteerde transtorakale biopsies wat deur 'n
pulmonoloog uitgevoer is, haalbaar, veilig, prakties en goedkoop is en dat dit 'n hoë opbrengs
het met betrekking tot diagnose.
• Utility of rapid on-site evaluation of transbronchial needle aspirates (Respiration
2005;72:182-8)
Hierdie publikasie het die ekonomiese voordele van spoedige in-teater evaluasie van
transbrongiale monsters bevestig in 'n gesondheidsisteem met beperkte fondse.
• Transbronchial needle aspirates: comparison of two preparation methods (Chest
2005;127:2015-8)
Hierdie studie het bewys dat in-teater voorbereiding van skyfies ‘n baie beter diagnostiese
opbrengs lewer as om al die aspirate in ‘n enkele houer in te spuit. Dit het impliseer dat die
opbrengs verbeter is sonder enige addisionele kostes.
• Transbronchial needle aspirates: how many passes per target site? (European
Respiratory Journal 2007;29:112-6)
Hierdie studie het die mees ekonomiese en effektiewe benaderings tot die seriële
monsterneming met transbrongiale naald aspirasie gedurende veselskope ondersoek.
• Ultrasound assisted transthoracic biopsy: fine needle aspiration or cutting needle
biopsy? (European Respiratory Journal 2007;29:357-62)
Hierdie artikel het twee algemene metodes van monsterneming vergelyk en het getoon dat die
goedkoper metode voldoende is in die meerderheid van gevalle.
2.4. Gevolgtrekking
Hierdie navorsing het ‘n beduidende inpak gehad op huidige kliniese praktyk. Konvensionele
metodes is geoptimaliseer deur tegniese faktore te verbeter en deur die integrasie van
interdissiplinêre samewerking. Die geïnisieërde navorsing is voortgaande en streef daarna om
nuwe tegniese en ekonomiese verbeteringe in die diagnose van tumore van die toraks te
bewerkstellig.
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84. Background, literature review and research plan
4.1. Chest tumors
Tumors of the the chest represent a common clinical problem for the chest physician. For the
purpose of this work, chest tumors as a group are functionally defined as abnormal chest
masses detectable on a radiograph, which can arise from the lungs, the pleura, the anterior
mediastinum and the chest wall. Examination of chest tumors is an interdisciplinary task
which requires close collaboration of pathologist, physician and radiologist.
4.1.1. Lung tumors
Lung tumors are best classified into benign (infectious granuloma, benign neoplasms,
inflammatory, other) and malignant (small cell and non small cell bronchogenic carcinoma,
carcinoid, metastatic lesions). The most frequent lung mass is primary lung cancer, which is
currently the most common cause of cancer mortality throughout the world [1]. The major
histologic types of lung cancer include small cell carcinoma and the non-small cell carcinoma
types of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [2]. The
International Staging System for non-small cell lung cancer relies on scoring the extent of the
primary tumor (T), lymph node involvement (N) and the presence of distant metastases (M),
the combination of which will define a clinical stage I-IV [3]. The single most important
prognostic factor is mediastinal lymph node involvement.
4.1.2. Pleural tumors, anterior mediastinal tumors, chest wall tumors
Malignant pleural mesothelioma is by far the most frequent pleural tumor. Its differential
diagnosis is not wide but includes both benign and malignant processes [4]. The main
challenge in diagnosing malignant mesothelioma is the distinction from metastatic
adenocarcinoma. Possible primary sources for the latter include lung, breast, stomach,
kidney, ovary, and prostate.
Lesions most commonly found in the anterior mediastinum are thymomas, germ cell tumors,
lymphomas, intrathoracic thyroid tissue, and parathyroid lesions. Thymomas are the most
common anterior mediastinal primary neoplasm in adults [5]. Primary mediastinal lymphoma
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primary anterior mediastinal mass [6]. Germ cell tumors account for 15% of anterior
mediastinal tumors in adults [7].
Most tumors clinically imposing as derived from the chest wall are in fact metastases from
distant primary tumors or tumors extending from the lung or pleura into the chest wall. The
differential diagnosis of genuine chest wall tumors includes benign or malignant neoplasms
of bone and cartilage (osteochondroma, osteochondrosarcoma). Rarely, a solitary
plasmacytoma can present as a lytic rib lesion.
4.2. Sampling techniques
In pursuing a tissue diagnosis of a chest tumor, there is a range of procedures to choose from.
If there is evidence of supraclavicular nodal involvement or of an easily accessible metastatic
site such as a pleural effusion, then these should be assessed first. Sputum cytology is a non-
invasive study with a high specificity, but a positive finding of cancer is only helpful if the
patient is not a surgical candidate because of anatomic location of the lesion or severe
physiologic limitations. All other patients will undergo either bronchoscopy or a transthoracic
biopsy.
4.2.1. Transbronchial needle aspiration (TBNA)
TBNA is an elegant and effective sampling method [8]. A short, protected and disposable
needle attached to a flexible plastic catheter is introduced via flexible bronchoscope and can
be inserted into the lesion of interest under direct vision [9]. In lung cancer, TBNA often
establishes the diagnosis and provides staging information in a single procedure [10].
Although of proven value also in non-malignant and in infectious disease TBNA remains
underutilized [11, 12]. One reason might be that there are still aspects of TBNA that await
clarification. Technical issues are for instance the number of needle passes that are required
to provide a diagnosis at a certain site, and whether this number of passes varies in different
clinical situations.
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4.2.2. Transthoracic needle aspiration (TTNA) and ultrasound (US)
TTNA of the lung is a well-established method in the diagnosis of pulmonary nodules. The
reported diagnostic accuracy of computed tomography (CT) guided TTNA is greater than
80% for benign disease and greater than 90% for malignant disease [13]. Transthoracic
ultrasound (US) of the chest is useful in the evaluation of a wide range of peripheral
parenchymal, pleural, and chest wall diseases [14]. A recent review about ultrasound
techniques for chest physicians published by the applicant is attached [15]. Although US is
inexpensive, comfortable, mobile and relatively easy to learn, most chest physicians are not
familiar with US. In order to promote US guided biopsy as a routine tool for chest physicians
a straight forward, simple and safe method to perform US guided biopsies needs to be
developed. However, it is unclear whether the number of patients with suitable tumors is
large enough for sustaining such a routine procedure. Also, it is not clear if chest physicians
can reach the same levels of safety and yield as specialist radiologists.
4.2.3. Sample types and sample handling
The importance of proper handling of the obtained specimen is a critical aspect of biopsy
procedures which is in stark contrast to the paucity of literature covering the subject. Work
needs to be done to establish standard protocols as to how to harvest good specimens from
chest tumors for cytology. In TTNA, it is unclear whether a histological sample or a fine
needle aspiration are preferable for safety and yield. In TBNA, it is unclear whether needle
aspirates should be smeared directly or conserved in alcohol for later processing [16].
One of the most important issues in tumor diagnosis is close communication between
pathologist and clinician. Rapid on-site evaluation (ROSE) of the specimen by a
cytopathologist present in theatre has been demonstrated to increase the diagnostic yield in
transbronchial needle aspiration [17, 18]. However, ROSE is not widely practiced and has
never been validated for transthoracic samples.
4.3. Integration of sampling and analysis
Given the economical pressure the local health care system is being subjected to, it is clear
that diagnostic procedures in chest tumors must be developed to preferably employ the safest,
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least invasive, and least costly tests in a given situation. For the potentially operable patient
with suspected lung cancer, bronchoscopy with direct examination of the visible airways is
the preferred initial invasive diagnostic procedure. The principal goal is to diagnose and
pathologically stage the patient's tumor at the same time. This can be achieved with TBNA
applied to the primary lesion and mediastinal nodes. There is scope for technical refinements
as well as for collaboration with cytopathologists for the analysis of samples.
Patients with potentially resectable lesions after non-contributory bronchoscopy, patients
with suspected non-resectable lung cancer or patients who prefer conservative treatment over
surgery are candidates for a transthoracic procedure. For larger peripheral-based lung tumors,
pleural, chest wall and anterior mediastinal lesions, ultrasound is an ideal but underused
guiding method of choice for the physician. A practical method needs to be developed for
US-assisted fine needle aspiration and for core biopsy, and the respective indications for both
need to be clarified. Further, ROSE confirming adequacy of the retrieved specimen could
avoiding the need for a histological biopsy.
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5. Outline
5.1. Aim
To better integrate transbronchial needle aspiration, transthoracic ultrasound guided needle
biopsy as well as rapid on-site analysis of samples in theatre into clinical routine practice.
5.2. Objectives
• To explore TBNA as the leading bronchoscopic sampling tool
• To develop an ultrasound-guided TTNA technique
• To improve sample collection and processing techniques for TBNA and TTNA
• To integrate cytopathological ROSE for TBNA and TTNA
• To investigate synergisms between ROSE and needle aspiration techniques
• To estimate the economical impact of these methods
5.3. Methods and logistics
This work was subdivided into single goal-orientated studies which are designed to result in
independent scientific publications. These publications are the output of this work.
5.4. Statistical aspects
Expert statistical support has been received for each study if required (Martin Kidd, Center
for Statistical Consultation, University of Stellenbosch). The statistical aspects are study
specific and described in detail in the single papers.
5.5. Ethics
Most of this work consisted in observation, documentation and analysis of routine clinical
procedures. Ethics Committee approval was obtained for studies with TBNA and on-site
cytology (project number: 2003/180) and for transthoracic biopsy (project number:
2003/177).
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6. Published studies derived from this thesis
Five studies published by the applicant as the first author in international peer-reviewed
journals form the main part of this thesis. The abstracts of the studies are displayed on the
following pages. The complete studies are attached as Appendix 1-5.
• Safety and yield of ultrasound-assisted transthoracic biopsy performed by
pulmonologists  [19]
Respiration 2004;71:519-22
• Utility of rapid on-site evaluation of transbronchial needle aspirates  [20]
Respiration 2005;72:182-8
• Transbronchial needle aspirates: comparison of two preparation methods  [21]
Chest 2005;127:2015-8
• Transbronchial needle aspirates: how many passes per target site?  [22]
European Respiratory Journal 2007;29:112-6
• Ultrasound assisted transthoracic biopsy: fine needle aspiration or cutting needle
biopsy?  [23]
European Respiratory Journal 2007;29:357-62
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6.1. Study 1
6.1.1. Citation:
Diacon AH, Schuurmans MM, Theron J, Schubert PT, Wright CA, Bolliger CT. Safety and
yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists. Respiration
2004;71:519-522.
6.1.2. Abstract:
BACKGROUND: Transthoracic ultrasound (US) has gained popularity as a tool for
visualizing pleural effusions and assisting thoracentesis or chest drain placement. In the
absence of effusion, US just as well demonstrates solid masses involving or abutting the
pleura, yet biopsy of such lesions is not widely performed by chest physicians.
OBJECTIVE: To assess the feasibility and the safety of US-assisted cutting needle biopsy
performed by chest physicians in routine practice.
METHODS: Lesions involving or abutting the pleura > or =20 mm in diameter on US were
sampled with a 14-gauge cutting needle under local anesthesia. Biopsy site, needle direction
and depth of penetration were determined with US. The procedure was performed without
direct US guidance in 'free-hand' technique.
RESULTS: Ninety-one patients underwent 96 cutting-needle biopsies for suspected
peripheral lung tumors (n = 44, 46%), pleural-based (n = 39, 41%), mediastinal (n = 10,
10%), or chest wall lesions (n = 3, 3%), which were single in 71%, multiple in 6% and
diffuse in 23%. Sensitivity for malignant neoplasms (n = 65) was 85.5% and 100% for
mesothelioma (n = 10). Pneumothorax occurred in 4%.
CONCLUSIONS: US-assisted cutting-needle biopsy of lesions > or =20 mm in diameter is
safe in the hands of pulmonologists. The yield for neoplastic disease including mesothelioma
is high.
http://scholar.sun.ac.za
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6.2. Study 2
6.2.1. Citation:
Diacon AH, Schuurmans MM, Theron J, Louw M, Wright CA, Brundyn K, Bolliger CT.
Utility of rapid on-site evaluation of transbronchial needle aspirates. Respiration
2005;72:182-188.
6.2.2. Abstract:
BACKGROUND: Rapid on-site evaluation has been proposed as a method to improve the
yield of transbronchial needle aspiration.
OBJECTIVES: This study investigated whether on-site analysis facilitates routine diagnostic
bronchoscopy in terms of sampling, yield and cost.
METHODS: Patients with lesions accessible for transbronchial needle aspiration on
computed tomography were investigated. A cytopathologist screened the needle aspirates on
site for the presence of diagnostic material. The bronchoscopic sampling process was
adjusted according to the results. In 90 consecutive patients with neoplastic disease (n=70;
78%), non-neoplastic disease (n=16; 18%) or undiagnosed lesions (n=4; 4%) we aspirated
162 lung tumors or lymph node sites (mediastinal: 7%; tracheobronchial: 68%; other: 25%).
RESULTS: The diagnostic yield of needle aspiration was 77 and 25% in patients with
neoplastic and non-neoplastic lesions, respectively. Sampling could be terminated in 64% of
patients after needle aspiration had been performed as the only diagnostic modality, and on-
site analysis identified diagnostic material from the first site aspirated in 50% of patients.
Only in 2 patients (2%) diagnostic aspirates were not recognized on site. On-site analysis was
cost effective due to savings for disposable diagnostic tools, which exceeded the extra
expense for the on-site cytology service provided.
CONCLUSIONS: Rapid on-site analysis of transbronchial aspirates is a highly useful,
accurate and cost-effective addition to routine diagnostic bronchoscopy.
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6.3. Study 3
6.3.1. Citation:
Diacon AH, Schuurmans MM, Theron J, Brundyn K, Louw M, Wright CA, Bolliger CT.
Transbronchial needle aspirates: comparison of two preparation methods. Chest
2005;127:2015-8.
6.3.2. Abstract:
STUDY OBJECTIVES: Transbronchial needle aspiration has evolved as a key
bronchoscopic sampling method. Specimen handling and preparation are underrated yet
crucial aspects of the technique. This study was designed to identify which of two widely
practiced sample preparation methods has a higher yield.
DESIGN: Prospective comparison of two diagnostic methods.
SETTING: Tertiary academic hospital.
PATIENTS: Consecutive patients undergoing transbronchial needle aspiration.
INTERVENTIONS: Transbronchial aspirates were obtained pairwise. One specimen was
placed directly onto a slide and smears were prepared on site (ie, the direct technique), and
the other specimen was deposited into a vial containing 95% alcohol and further prepared in
the laboratory (ie, the fluid technique). In total, 282 pairs of samples were aspirated from 145
target sites (paratracheal, 10 sites; tracheobronchial, 101 sites; hilar, 17 sites; endobronchial
or peripheral, 17 sites).
MEASUREMENTS AND RESULTS: The measured outcome was the presence of diagnostic
material at the final laboratory assessment. At least one diagnostic aspirate was obtained in
66% of 86 investigated patients (small cell lung cancer, 18 patients; non-small cell lung
cancer, 47 patients; other diagnoses, 21 patients). The direct technique had a better yield
overall than the fluid technique (positive aspirates, 36.2% vs 12.4%, respectively; p < 0.01),
as well as after stratification for tumor type and for anatomic site.
CONCLUSION: The direct technique is superior to the fluid technique for the preparation of
transbronchial needle aspirates.
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6.4. Study 4
6.4.1. Citation:
Diacon AH, Schuurmans MM, Theron J, Brundyn K, Louw M, Wright CA, Bolliger CT.
Transbronchial needle aspirates: how many passes per target site? European Respiratory
Journal 2007;29:112-6.
6.4.2. Abstract:
Transbronchial needle aspiration is a bronchoscopic sampling method for a variety of
bronchial and pulmonary lesions. This study investigated whether and how serial needle
passes contribute to the yield of transbronchial needle aspiration at specific target sites.
We prospectively recorded 1562 needle passes performed at 374 target sites rated for
anatomical location, size, bronchoscopic appearance and underlying disease in 245 patients
with neoplastic disease (82%), non-neoplastic disease (15%) or undiagnosed lesions (3%).
Positive aspirates were obtained in 75% of patients and in 68% of target sites. A diagnosis
was established with the first, second, third and fourth needle pass at 64%, 87%, 95% and
98% of targets, respectively. The absolute yield varied strongly with target sites features, but
the stepwise increment to the maximum yield provided by serial passes was similar across
target sites.
Three transbronchial needle passes per site are appropriate when only a tissue diagnosis is
sought and when alternative sites or sampling modalities are available. At least four or five
passes should be carried out at lymph node stations critical for staging of lung cancer.
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6.5. Study 5
6.5.1. Citation:
Diacon AH, Theron J, Schubert P, Brundyn K, Louw M, Wright CA, Bolliger CT.
Ultrasound assisted transthoracic biopsy: fine needle aspiration or cutting needle biopsy?
European Respiratory Journal 2007;29:357-62.
6.5.2. Abstract:
This study compared the diagnostic yield of ultrasound assisted cutting needle biopsy (CNB)
and fine needle aspiration biopsy (FNAB) in chest lesions.
A physician performed ultrasound and FNAB with a 22G spinal needle in all patients directly
followed by 14G CNB in patients without contraindication.
We prospectively included 155 consecutive lesions arising from the lung (74%), pleura
(12%), mediastinum (11%), or chest wall (3%) in patients with a final diagnosis of lung
carcinoma (74%), other malignant tumors (12%), non-neoplastic disease (9%), or unknown
(5%). The overall diagnostic yield was 87%. Combined specimens were obtained in 123
lesions (79%). In these, yields of FNAB, CNB and both methods combined were 82%, 76%
and 89%, respectively. FNAB was superior to CNB in lung carcinoma (95% versus 81%,
p=0.006), but CNB was superior in non-carcinomatous tumors and in benign lesions. On-site
cytology was 90% sensitive and 100% specific for predicting a positive FNAB. One patient
required drainage for pneumothorax (0.6%).
Ultrasound assisted FNAB performed by chest physicians is an accurate and safe initial
diagnostic procedure in patients with a high clinical probability of lung carcinoma. All other
patients should undergo concurrent FNAB and CNB.
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7. Discussion
7.1. General
This work has shown that improvements in biopsy and analysis techniques in tumors arising
from the chest wall, pleura, anterior mediastinum and lung can be achieved by innovative use
of existing resources in a setting with limited access to cutting edge technology. The
substance of the work is probably best illustrated with the example of TBNA, a field where
several research groups around the globe compete in developing strategies to improve TBNA
yield and accuracy. It is becoming more and more evident that the regular use of TBNA for
staging of lung cancer significantly reduces the number of futile surgical interventions in
patients whose disease is too advanced for curative resection [24, 25]. Despite the high
relevance of a positive TBNA, the major limitation of TBNA is the widely variable
sensitivity that ranges between 39% and 78% in recent meta analyses [26, 27]. Across
studies, the prevalence of mediastinal metastasis in the study population is the main
determinant of sensitivity. Other factors include the size and location of the lesions, the kind
of needle employed, the number of aspirates performed, and the experience and the skill of
the operator [28, 29]. Because TBNA for staging of lung cancer is basically a blind
procedure, different guiding systems for TBNA have been proposed to improve sensitivity.
The first proposed guidance system to direct TBNA was CT-fluoroscopy with a reported
increase in TBNA sensitivity by 40% [30]. However, this method is cumbersome and did not
gain popularity. An established TBNA guidance system is transbronchial ultrasound (EBUS).
In a randomised controlled trial with 200 patients traditional TBNA was compared with
EBUS-guided TBNA. The latter makes use of a flexible ultrasound probe introduced through
the working channel of the bronchoscope to locate the target lesion. There were no significant
differences in sensitivity between conventional TBNA and EBUS guided TBNA for right
paratracheal and subcarinal lymph nodes, but significantly better results for left paratracheal
and high paratracheal lymphnodes [31]. An even newer type of bronchoscope allows TBNA
and endosonography to be performed simultaneously instead of sequentially, so that the tip of
the needle can be observed in real time while it is being inserted into the target. Initial results
obtained with this method report a sensitivity surpassing 90%, regardless of the lymph node
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location or size [32-34]. A further technology recently proposed to guide TBNA is an
electromagnetic navigation system, which guides the tip of the bronchoscope to a lesion
based on a three dimensional CT reconstruction of the patient’s lung and tracheobronchial
tree. The reported sensitivity value of 100% will need to be confirmed with further studies
[35]. ROSE, the technique developed with the work presented in this thesis, takes a different
approach to increasing TBNA yield. While all the technical innovations cited above at best
demonstrate in “real-time” that a sample has been harvested from a lesion of interest, ROSE
provides “real-time “ qualitative information about that sample’s diagnostic significance.
Compared to the techniques mentioned above, ROSE does not only cost very little but also
provides the opportunity to terminate a procedure when its diagnostic objective has been met.
There is considerably less scientific activity on the field of transthoracic ultrasound than with
TBNA. US has been overlooked by chest physicians for many years, despite its multiple
advantages for the practice of chest medicine. Several review articles have recently
emphasized the importance of US for the chest physician. US can be performed by means of
the most basic equipment. It can investigate chest wall abnormalities, pleural thickening and
pleural tumors as well as describe qualitative and quantitative aspects of a pleural effusion.
US can visualise lung tumors and other parenchymal pulmonary processes provided they abut
the pleura, and it is the ideal tool to assist with thoracocentesis and drainage of effusions [36-
38]. A recent publication confirmed that US is useful for the exclusion of a post-procedural
pneumothorax [39].
7.2. Impact of this work on our clinical practice
A very active interdisciplinary collaboration with the Department of Anatomical Pathology
has been established and is ongoing on a clinical as well as academic level. This work has
produced considerable improvements in routine diagnostic procedures for the diagnosis of
chest tumors over the previous standard. Ultrasound-assisted TTNA and flexible
bronchoscopy with TBNA as the leading sampling method make up more than half of all
diagnostic procedures of chest tumors in our bronchoscopy theaters to date. Specialist
registrars are trained to perform these procedures. Without embarking on major investments
for new technologies, our diagnostic yield has been considerably increased by the routine
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addition of rapid on-site evaluation of specimens. In turn, procedures yielding a sample
suitable for ROSE have been developed and promoted. One more study was completed while
awaiting review and publication of the papers covered in this thesis. The study dealt with
evaluating different staining modalities for rapid on-site evaluation of transbronchial needle
aspirates. The abstract was presented at the European Respiratory Conference 2006. As this
study is not a formal part of this thesis it is presented in the Appendix only in abstract form.
7.3. Impact of this work beyond our own practice
The results of this work have been met with considerable interest on an international level.
There seems to be a need for additional information and more in-depth instruction regarding
the optimal use of conventional diagnostic tools. The candidate has received invitations to
speak at and chair sessions about interventional bronchoscopy. A regular exchange of
research fellows interested in interventional procedures has been established. Owing to our
increasing international reputation it has been possible to obtain sponsorships for both
diagnostic instruments as well as consumables, which are currently provided free of charge
from several institutions situated in Switzerland, Germany and the Netherlands.
7.4. Outlook
Indications and technique of 22G and 21G TBNA are well documented. These small-
diameter transbronchial needles are safe, relatively easy to handle and harvest high-quality
cytological specimens. In comparison, little research has gone into larger bore TBNA (20G,
19G). Such needles are technically more challenging to use and there is a perceived (but as
yet unproven) increased risk of bleeding. Cytology alone is sometimes not sufficient to
diagnose non-carcinomatous mediastinal lymphadenopathy. This problem typically arises in
cases of sarcoidosis, tuberculosis (TB) and lymphoma, where material suitable for
histological preparation would be preferable. Large bore needles designed to harvest
histological samples are available on the market, but standard procedures for their use are
lacking. Such needles typically harvest a mixture of loose cells and fragments of tissue.
These fragments are often of an intermediate size, which is not quite large enough for routine
histological preparation and still too big for preparing a thin cytological smear. The ideal
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preparation method for large-bore TBNA samples should combine the advantages of
cytological and histological preparation. Large-bore TBNA offers research opportunities into
preparation methods, clinical indications and procedural techniques.
Another area in need of research is the diagnosis of TB in mediastinal lymph nodes. TB
presenting as mediastinal lymphadenopathy is becoming more frequent with the rising
proportion of patients with retroviral disease. Children often present with intrathoracic
lymphadenopathy, which might be easily diagnosed with TBNA. How to best prepare TBNA
samples for the diagnosis of TB is not entirely clear. It has become our routine to rinse the
fresh sample directly into a Mycobacterium Growth Indicator Tube (MGIT) without prior
decontamination. This appears to yield good results but still needs formal validation. Such
research could start with cervical lymphadenopathy and standard manual aspiration
techniques. Different methods for TB culture could be validated on such samples. There is an
abundance of cervical lymph node aspirates available from patients with TB, carcinoma or
other infective diseases. Once the technique is established on cervical aspirates, it could be
tested further on TBNA samples. As a further topic, the different immune responses in
cervical or mediastinal lymph node tuberculosis could be studied on such samples.
The value of transthoracic ultrasound for chest physicians is still incompletely researched.
One area of interest is the potential role of ultrasound guided aspiration in parenchymal
inflammatory processes, such as the lung infiltrates observed in lobar pneumonia or acute
respiratory distress syndrome (ARDS). Little is known about the pleural morphology in cases
with exudative pleural effusion. Subtle changes are visible with transthoracic ultrasound, but
the diagnostic value of these observations is unknown. It is also plausible that “blind” pleural
biopsies could be directed towards areas with ultrasonographic pathology, thus increasing the
diagnostic yield.
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Abstract
Background: Transthoracic ultrasound (US) has gained
popularity as a tool for visualizing pleural effusions and
assisting thoracentesis or chest drain placement. In the
absence of effusion, US just as well demonstrates solid
masses involving or abutting the pleura, yet biopsy of
such lesions is not widely performed by chest physi-
cians. Objective: To assess the feasibility and the safety
of US-assisted cutting needle biopsy performed by chest
physicians in routine practice. Methods: Lesions involv-
ing or abutting the pleura 620 mm in diameter on US
were sampled with a 14-gauge cutting needle under
local anesthesia. Biopsy site, needle direction and depth
of penetration were determined with US. The procedure
was performed without direct US guidance in ‘free-hand’
technique. Results: Ninety-one patients underwent 96
cutting-needle biopsies for suspected peripheral lung
tumors (n = 44, 46%), pleural-based (n = 39, 41%),
mediastinal (n = 10, 10%), or chest wall lesions (n = 3,
3%), which were single in 71%, multiple in 6% and dif-
fuse in 23%. Sensitivity for malignant neoplasms (n = 65)
was 85.5% and 100% for mesothelioma (n = 10). Pneu-
mothorax occurred in 4%. Conclusions: US-assisted cut-
ting-needle biopsy of lesions 620 mm in diameter is safe
in the hands of pulmonologists. The yield for neoplastic
disease including mesothelioma is high.
Copyright © 2004 S. Karger AG, Basel
Introduction
Modern ultrasound (US) units are mobile, light-weight
and affordable. In recent years, chest physicians have
come to appreciate US as a quick and versatile bedside
aid for assessing pleural effusions and assisting thoracen-
tesis or chest drain placement. US also demonstrates pleu-
ral-based masses and lung tumors in the absence of a pleu-
ral effusion, provided they are involving or abutting the
pleura [1, 2]. Such lesions are suitable for cutting-needle
biopsy after identification of a puncture site with US,
which has distinct potential advantages in this setting.
Firstly, large vessels and aerated lung parenchyma can
easily be detected with US, which minimizes the risk of
For editorial comment see p. 448
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pneumothorax and improves safety. Secondly, US can be
performed at the bedside and in any body position allow-
ing for swift procedures with minimal distress even in
patients in poor general condition. Thirdly, the integra-
tion of US into a ‘low-tech’ procedure by chest physicians
can reduce the need for more expensive radiological or
surgical biopsy. This study prospectively assessed the
safety and yield of US-assisted transthoracic cutting-nee-
dle biopsies performed by pulmonologists in routine prac-
tice.
Patients and Methods
Patient Selection
Patients referred to the Lung Unit of Tygerberg Hospital (tertiary
academic center, catchment area 1.5 million) with pleural-based
tumors on chest radiography or computed tomography (CT) were
candidates for the study. Patients with pleural effusions were not
enrolled but further evaluated with pleural fluid cytology or thoracos-
copy. Lesions invisible or too small for biopsy on US were further
investigated with appropriate means. All patients signed informed
consent, and ethical approval from the institutional review board
was obtained.
Biopsy Procedure
Lesions extending at least 20 mm in any accessible dimension on
US (Toshiba Sonolayer L SAL 77A) were selected. A consultant
respiratory physician or a registrar under supervision performed son-
ography and biopsy in a bronchoscopy suite without specialist radiol-
ogy support. Preferred patient position for the biopsy was sitting
upright on a stretcher with arms resting on a bedside table, but supine
or lateral decubitus positions were also employed according to tumor
location and patient preference. The operator determined the biopsy
site using a standard 3.75-MHz sector probe and memorized direc-
tion and depth of penetration. As we aimed for a simple and straight-
forward procedure, the biopsy was performed in ‘free-hand’ tech-
nique without direct US observation. Care was taken to avoid inter-
costal and mammarian arteries. We used a manually operated 14-
gauge Tru-cut biopsy needle with a specimen notch of 20 mm (Alle-
giance, Chateaubriand, France). Under local anesthesia, two or more
passes were performed until macroscopically satisfactory material
was harvested, which was routinely processed for histological evalua-
tion. Additional tests were requested at the discretion of the physi-
cian performing the biopsy. Directly after the procedure, the site was
re-examined with US. A follow-up chest radiography was obtained if
the pre- and post-biopsy sonar finding differed and at the discretion
of the physician. All patients were observed for at least 2 h before
discharge.
Assessments and Measurements
Lesions were classified on radiological appearance for the most
likely origin as ‘pleural’ (pleural based, blunt angle to the lung), ‘pul-
monary’ (lesion with center in the lung, acute angle to the pleura),
‘chest wall’ (lesions centered in the chest wall with pleural involve-
ment), or ‘mediastinal’ (lesions predominantly located in the anterior
mediastinum with extension to the pleura), and for distribution as
‘single’, ‘multiple’, or ‘diffuse’. A history of a recent non-diagnostic
bronchoscopy was noted as a marker for a peripheral and circum-
scribed lesion. As an indication for locally advanced disease, we
recorded the presence of superior vena cava syndrome or signs of
direct spread into nervous tissue (nerve roots, spinal cord, brachial
plexus), which both mean surgical non-resectability in the setting of
non-small cell lung cancer.
Scoring
Histology was classified as ‘diagnostic’ or ‘non-diagnostic’ (nor-
mal tissue, not representative tissue, or representative but necrotic
tissue). Two pathologists independently reviewed all specimens. For
calculation of sensitivity and specificity, histological diagnosis of a
specific neoplastic disease was accepted as true positive for malig-
nancy. True negative for malignancy were lesions with non-malig-
nant histology if confirmed by surgical biopsy, microbiological cul-
ture or radiological follow-up documenting a stable or receding lesion
over at least 6 months. Likewise, cases with non-diagnostic histology
but stable or receding lesions on follow-up were rated true negative.
All other non-diagnostic biopsies were considered false negative.
Statistical Analysis
As this was mainly an observational study, no formal sample size
calculation was performed. As we considered the yield for mesothe-
lioma a pivotal factor for the practical value of the procedure, we
arbitrarily enrolled consecutive patients until 10 cases of mesothelio-
ma had been diagnosed. To detect a potential ‘learning effect’ during
the study, the incidence of complications in the first and second half
of the series was compared with a ¯2 test.
Results
Patients and Lesions
Over a 24-month period, 91 patients underwent 96
biopsies for 44 suspected peripheral lung tumors (46%),
39 pleural-based (41%), 10 mediastinal (10%) and 3 chest
wall lesions (3%), which were single in 71%, multiple in
6% and diffuse in 23%. Seventy-four percent were male,
mean age was 56 years (range: 18–80), and 38% were out-
patients. Most lesions presented either as single lung
lesion extending to the pleura (71%) or as diffuse pleural
thickening (23%). A chest radiography was available in all
and a chest CT scan in only 65 patients (68%). A peripher-
al lung lesion undiagnosed on bronchoscopy was noted in
24 patients (25%) and locally advanced disease with
involvement of the superior vena cava or nervous tissue
in 27 (28%). Mean maximal lesion thickness perpendicu-
lar to the pleura was 54 mm (range: 20–100 mm).
Procedures and Adverse Events
Mean procedure time was 25 min (range: 10–85 min).
The biopsies were generally well tolerated. A pneumotho-
rax was observed in 3 patients. Two of these had a lung
lesion !30 mm in diameter which was not adherent to the
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Table 1. Patients and histological diagnosis
Diagnosis All patients
(n = 91)
n %
Pleural lesions
(n = 39)
n %
Diagnostic biopsies 76 84 33 85
Malignant lesions 65 71 24 62
Small cell lung cancer 14 15 4 10
Non-small cell lung cancer 35 38 8 21
Mesothelioma 10 11 10 26
Metastasisa 4 4 1 3
Sarcoma, myeloma 2 2 1 3
Benign lesions 11 12 19 49
Fibrosis 8 9 8 21
Solitary fibrous tumor 1 1 1 3
Involuted echinococcus cyst 1 1 0 0
Tuberculoma 1 1 0 0
Non-diagnostic biopsies 15 16 6 15
Diagnosis made surgicallyb 4 4 3 8
Lesion resolved on follow-up 4 4 3 8
Undiagnosed 7 8 0 0
a Germ cell tumor (n = 2), renal carcinoma (n = 2).
b Fibrosarcoma, hemangio-endothelioma, large cell lung cancer, solitary fibrous tumor
(n = 1 each).
parietal pleura. Although diagnostic material was har-
vested in both lesions, movement with respiration proba-
bly led to incidental puncture of lung tissue. The other
patient had a lesion of 60 mm in diameter which was cen-
trally necrotic. A biopsy of the very periphery of the lesion
was diagnostic for squamous cell carcinoma, but led to a
small pneumothorax. An additional patient with severe
chronic obstructive pulmonary disease reported increased
dyspnea immediately after the procedure, and a small-
bore chest drain was prophylactically inserted in theater.
No air leak was later found, however, and the dyspnea
subsided on inhalation of bronchodilators. Although it
remained unclear whether this patient had a biopsy-
induced pneumothorax, we calculated the rate of pneu-
mothorax as 4% (including this patient), with a pleural
drain inserted in 2% of all procedures. One case with a
superficial wound hemorrhage required a single skin su-
ture (1%). This patients had obstruction of the superior
vena cava, which predisposed to bleeding from collateral
veins situated in the chest wall. Minor events were tran-
sient pain requiring medication (n = 5), mild and transito-
ry hemoptysis (n = 2) and vasovagal reaction (n = 2). Nine
complications occurred in the first half versus five in the
second half of the series, but this difference was not statis-
tically significant (p = 0.22).
Specimens and Histology 
Diagnostic specimens were obtained in 76 patients
(84%, table 1). Most malignant lesions were non-small
cell lung cancers. Detection of malignancy had a sensitivi-
ty of 85.5% and a specificity of 100%, with a positive and
negative predictive value of 100 and 57.7%, respectively.
Thirty-eight out of 44 lesions !50 mm (86%) and 38 out
of 47 lesions 650 mm (81%) were diagnostic. Lesion size
did not correlate with positive histology (not significant,
¯2 test). Seven (8%) of 15 patients (16%) with initial non-
diagnostic biopsies remained undiagnosed. These pa-
tients were suffering from advanced neoplastic disease,
and further investigations were not undertaken due to
patient preference or lack of potential change of outcome.
However, all these cases had clinical features that were
not compatible with mesothelioma. We therefore deter-
mine the yield of cutting-needle biopsy for malignant
mesothelioma in this series as 100%. All mesotheliomas
could be diagnosed on the first biopsy procedure.
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Discussion
This prospective study shows that US-assisted cutting-
needle biopsy performed by a pulmonologist is safe and
effective in lesions 620 mm in diameter abutting or
involving the pleura. In a spectrum of disease representa-
tive for general practice, the sensitivity of the procedure
for neoplastic disease was 85.5% and 100% for malignant
mesothelioma. The intervention was safe with a rate of
only 2% of pneumothorax requiring drainage. US is al-
ready widely used by pulmonologists as a bedside aid for
placing chest tubes and performing pleural interventions
in immobilized or ventilated patients [1]. In the dispute
about the general relevance of US for the pulmonologist,
this report supports the growing body of evidence that US
is set to integrate with the pulmonologist’s armamentar-
ium in the future.
Pleural fluid cytology is increasingly preferred over tra-
ditional closed needle biopsy for evaluating malignant
pleural effusions. Moreover, it has recently been shown in
cases with cytology-negative effusions that standard
Abrams needle biopsy has a lower sensitivity for pleural
neoplastic disease than CT-guided cutting-needle biopsy
(47 vs. 87%, respectively) [3]. This excellent result was
achieved in cases with minimal pleural thickening of
mainly !5 mm, which is out of range for the method stud-
ied here. However, the yield of 85.5% in the present study
suggests that ‘low-tech’ US assistance might substitute CT
guidance for lesions 620 mm in diameter, irrespective of
the presence of a pleural effusion. Moreover, physician-
operated US is far more accessible than CT in many
peripheral health-care facilities, and a simple and low-cost
diagnostic technique is particularly welcome in regions
with high asbestos exposure. Our high yield for mesothe-
lioma is corroborated by other recent reports [3–5]. All
these studies share the use of a cutting biopsy device. It
seems, therefore, that transsectional cutting biopsy speci-
mens are better suited for the histological diagnosis of
mesothelioma than Abrams needle biopsies, which are
small, superficial and prone to crush artifacts.
The low rate of adverse events in the present study con-
firms that the lesion size and needle type chosen for this
study were adequate. US has the inherent safety advan-
tage of visualizing only lesions not shielded by air-con-
taining tissue. Aerated lung is therefore not transversed
with the biopsy device, which makes pneumothorax and
air embolus unlikely when a closed cutting-needle system
is used. Yield and safety of the procedure might be further
improved with direct US guidance, which requires an
additional skilled person to operate the sonar transducer
while the biopsy is taken. This has recently been recom-
mended for biopsy of small lesions [1]. Further, 20- or 21-
gauge fine-needle aspiration (FNA) for direct on-site as-
sessment by a cytopathologist could obviate the need for a
histological sample. Pleural FNA has not been extensively
studied, however, and the type of lesion suitable for FNA
needs further evaluation. In summary, transthoracic US-
assisted cutting-needle biopsy is an excellent first-line
diagnostic tool for pleural-based lesions 620 mm in
diameter. It is a quick, low-cost, safe and well-tolerated
tool in the hands of pulmonologists and has a high sensi-
tivity for pleural-based malignancies.
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In this issue of Respiration, Diacon et al. [1] report
their work on ultrasound-assisted transthoracic cutting
needle biopsy performed by pulmonologists. Their results
are impressive with a low complication rate (4% devel-
oped pneumothorax) and high yield of diagnostic speci-
mens (85.5%). These figures are comparable with pre-
vious series reported by interventional or chest radiolo-
gists [2, 3]. Although a 0% pneumothorax rate has been
reported for lesions abutting the pleural surface [4], the
biopsies in their study were not performed under direct
ultrasound guidance and the patients were carefully se-
lected, with all lesions biopsied involving or abutting the
pleura and measuring at least 20 mm in diameter. Other
workers have shown that cutting needle biopsy of small
lesions can also be safely undertaken with an excellent
diagnostic yield [3]. However, direct ultrasound guidance
is necessary for smaller lesions to avoid inadvertent punc-
ture of aerated lung. Ultrasound-guided biopsy of small
lesions is technically more difficult and requires a greater
degree of training and experience than for lesions greater
than 3 cm, which, as has been shown by Diacon et al. [1]
can be safely performed ‘freehand’ without direct visual-
isation.
The paper raises a number of interesting points: ultra-
sound examinations and guided biopsies have traditional-
ly been performed by radiologists. With the advent of high
quality, portable and affordable ultrasound machines
there has been a rapid increase in ultrasound performed
by non-radiologists. This has significant advantages for
patient management: procedures that previously required
transport to the radiology department can quickly and
easily be performed in the outpatient clinic or at the bed-
side [5]. Even though ultrasound is operator dependent,
basic skills such as the detection of a pleural effusion, for
example, can be learnt in a short period, although a prior
report has shown that involvement in 200 or fewer cases
during the training period was not sufficient for physi-
cians to develop acceptable levels of competence in sono-
graphy [6]. At the other end of the spectrum, the skills
needed to perform more complex ultrasound-guided
biopsy of small focal lesions with a reliable yield and low
complication rate may require a longer period of train-
ing.
Whilst the pulmonologists of tomorrow fortunate
enough to be trained by Diacon et al. [1] will undoubtably
receive excellent training from a team with a track record
that speaks for itself, there are important factors to be con-
sidered before other centres decide to adopt a similar
practice. Although for the most part it does not really mat-
ter who performs transthoracic biopsies as long as effec-
tive training and clinical governance programs are in
place so that the performance figures reported in the stud-
ies by Diacon et al. [1] and others [2, 3] can be main-
tained, it is important particularly in the setting of lung
and pleural malignancy, that there is multidisciplinary
team involvement in order to decide the most appropriate
course for initial diagnosis and subsequent treatment. For
example in the case of a suspected lung cancer there may
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be many different ways in which a histological diagnosis
may be obtained, each performed by a different specialist,
e.g. transbronchial biopsy by the pulmonologist, percuta-
neous biopsy by the radiologist, video-assisted thoracos-
copy and biopsy by the thoracic surgeon. Each method
may have its own risks and benefits and the best approach
is undoubtably reached by discussion between specialists
at a regular meeting.
In summary Diacon et al. [1] should be congratulated
on a well-constructed and useful paper which has impor-
tant implications for the future.
Dr. Andrew Scarsbrook
Dr. Fergus Gleeson
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lymph nodes: 68%; other: 25%).  Results: The diagnostic 
yield of needle aspiration was 77 and 25% in patients 
with neoplastic and non-neoplastic lesions, respectively. 
Sampling could be terminated in 64% of patients after 
needle aspiration had been performed as the only diag-
nostic modality, and on-site analysis identifi ed diagnos-
tic material from the fi rst site aspirated in 50% of pa-
tients. Only in 2 patients (2%) diagnostic aspirates were 
not recognized on site. On-site analysis was cost effec-
tive due to savings for disposable diagnostic tools, which 
exceeded the extra expense for the on-site cytology ser-
vice provided.  Conclusions: Rapid on-site analysis of 
transbronchial aspirates is a highly useful, accurate and 
cost-effective addition to routine diagnostic broncho s-
copy. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Transbronchial needle aspiration (TBNA) via ﬂ exible 
bronchoscopy (FB) is a well-established sampling tool for 
a variety of malignant, infectious or granulomatous lung 
lesions  [1] . In the setting of non-surgical staging of lung 
cancer, TBNA has been shown to decrease the need for 
 Key Words 
 Bronchoscopy   Fine-needle biopsy   Lung neoplasms   
Cytodiagnosis   Transbronchial needle aspiration 
 Abstract 
 Background: Rapid on-site evaluation has been pro-
posed as a method to improve the yield of transbron-
chial needle aspiration.  Objectives: This study investi-
gated whether on-site analysis facilitates routine 
diagnostic bronchoscopy in terms of sampling, yield and 
cost.  Methods: Patients with lesions accessible for trans-
bronchial needle aspiration on computed tomography 
were investigated. A cytopathologist screened the nee-
dle aspirates on site for the presence of diagnostic mate-
rial. The bronchoscopic sampling process was adjusted 
according to the results. In 90 consecutive patients with 
neoplastic disease (n = 70; 78%), non-neoplastic disease 
(n = 16; 18%) or undiagnosed lesions (n = 4; 4%) we as-
pirated 162 lung tumours or lymph node sites (medias-
tinal: 7%; tracheobronchial: 68%; other: 25%). In 90 con-
secutive patients with neoplastic disease (n = 70; 78%), 
non-neoplastic disease (n = 16; 18%) or undiagnosed le-
sions (n = 4; 4%) we aspirated 162 lung lesions (paratra-
cheal tumours or lymph nodes: 7%; tracheobronchial 
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diagnostic thoracic surgery  [2–4] . TBNA is superior to all 
other sampling modalities in peribronchial and submu-
cosal disease and is on par with bronchoscopic forceps 
biopsy in endobronchial tumours with an average diag-
nostic yield of 80%  [4, 5] . TBNA improves the yield of 
FB when added to bronchial washing, brushing and for-
ceps biopsy  [5–10] . Despite all these positive aspects, 
however, TBNA is still underutilized  [1] . This has been 
ascribed to lack of formal training, difﬁ culties with needle 
handling, poor success rates and insufﬁ cient cytological 
laboratory support  [4, 11] .  
 Practical innovations to improve the usefulness of 
TBNA are required. Endobronchial ultrasound (EBUS) 
 [12, 13] and ﬂ uoroscopy with computed tomography 
(CT)  [14] for needle guidance have shown potential to 
increase the yield of TBNA, but their impact has been 
limited to date. Rapid on-site evaluation (ROSE) of trans-
bronchial aspirates by a cytopathologist present in the 
bronchoscopy theatre reduces the incidence of inade-
quate specimens  [15] and improved TBNA yield in ob-
servational studies  [16, 17] . A thus far undervalued ad-
vantage of ROSE is the opportunity to adjust sampling 
during FB based on the results obtained. With ROSE, the 
cytologist can declare that diagnostic material has been 
harvested in sufﬁ cient quantity and quality for a provi-
sional diagnosis as well as for all later laboratory require-
ments. Consequently, the pulmonologist can decide to 
waive further sampling taking the anatomical and clinical 
situation into account. Given an acceptable accuracy of 
ROSE, we hypothesized that this strategy would simplify 
and abbreviate bronchoscopic sampling. We speculated 
further that fewer sampling tools used and specimens sub-
mitted for analysis could compensate for the cost of the 
on-site cytology service. This study prospectively investi-
gated the diagnostic yield and accuracy of ROSE-TBNA 
as well as its potential to simplify the diagnostic process 
and reduce cost.  
 Methods 
 Patients and Procedures 
 We included consecutive patients scheduled for routine bron-
choscopy in whom a lesion on computed tomography (CT) ap-
peared accessible with TBNA, regardless of size, location or pre-
sumed diagnosis of the lesion. FB and TBNA (needle diameter 21 
or 22 gauge; Bard, Billerica, Mass., USA) were performed under 
topical anaesthesia (Lidocaine 1%) by operators experienced with 
the techniques. Sites for TBNA were chosen based on clinical tu-
mour stage, CT scan and intrabronchial ﬁ ndings. TBNA was al-
ways the ﬁ rst diagnostic modality. For staging of suspected lung 
cancer the potentially highest rated nodal site was sampled ﬁ rst. 
If staging was not of concern, the most promising site for provid-
ing a diagnosis was sampled ﬁ rst. A complete inspection of the 
bronchial system was performed in all patients before or after 
TBNA. 
 Rapid On-Site Evaluation of Specimens 
 The material aspirated was immediately expressed onto num-
bered glass slides. Of each aspiration, one slide was air-dried for 
subsequent staining in the laboratory and one was immersed in 95% 
ethanol for immediate rapid Papanicolaou staining  [18] . Sampling 
was continued during the stain, which takes 180 s to complete. The 
stained slide was screened by a cytopathologist, who continuously 
reported the ﬁ ndings and announced when sufﬁ cient diagnostic 
material had been recovered for (1) a provisional diagnosis and (2) 
for all ancillary tests required for its conﬁ rmation and reﬁ nement 
(conventional and immunochemical stains). The bronchoscopist 
modiﬁ ed or terminated the sampling process based on the informa-
tion provided by the cytopathologist. If no provisional diagnosis 
resulted from ROSE, sampling was continued with the appropriate 
additional modalities (brush, forceps biopsy, bronchoalveolar la-
vage, and bronchial wash). 
 Evaluation of ROSE and TBNA  
 All slides were transferred to the cytopathology laboratory and 
further processed with a Giemsa stain  [18] and with other stains or 
immunochemical methods if necessary. The deﬁ nitive TBNA di-
agnosis was established by a different cytopathologist with no 
knowledge of the on-site diagnosis. An aspirate was considered pos-
itive when it contained diagnostic material (clumps of cells with 
malignant features, or distinct features of granulomatous disease 
with or without necrosis). The provisional diagnosis issued on-site 
was compared to the ﬁ nal clinical diagnosis established in the pa-
tient after full clinical evaluation. A diagnosis of neoplastic disease 
was either surgically conﬁ rmed or corroborated by observation of 
a compatible clinical and radiological course under palliation. Tu-
berculosis was conﬁ rmed with either a positive stain for acid-fast 
bacilli or a positive culture of  Mycobacterium tuberculosis  on a re-
spiratory specimen. Sarcoidosis was veriﬁ ed with the histological 
presence of non-caseating granuloma and/or typical bronchoalveo-
lar lavage. The other diagnoses were made on clinical and radio-
logical grounds. 
 Time- and Cost-Effectiveness Analysis 
 Firstly, we established whether sampling was reduced and which 
sampling manoeuvers were avoided due to ROSE. For that pur-
pose, a detailed plan for specimen collection was recorded prior to 
each FB for the hypothetical situation that ROSE was not available. 
During FB, the sampling performed and the decisions based on 
ROSE were documented. Afterwards, the original plan was re-
viewed and adjusted for unexpected intrabronchial ﬁ ndings. This 
way we established an accurate alternative scenario for sampling 
without ROSE. Secondly, the person-minutes spent for both sce-
narios were compared. We stratiﬁ ed for three categories of health 
care professionals: (1) physicians (bronchoscopist and cytopatholo-
gist), (2) technologists (theatre nurse and cytology technician) and 
(3) administrative staff (porter service and secretaries). The analy-
sis included the whole sequence of specimen collection, transport, 
preparation, analysis and reporting, beginning with the bronchos-
copy and ending with the generation of the ﬁ nal report. This process 
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was divided into multiple speciﬁ c tasks, which were either directly 
timed or allocated a typical amount of person-minutes to be com-
pleted. On the basis of the person-minutes spent, thirdly, the salary 
costs of both scenarios were calculated on the basis of the 2002 lo-
cal salaries. Fourthly, the costs for consumable diagnostic tools 
were calculated based on the 2002 local distributors’ price list. Fi-
nally, a cost balance for both scenarios was created by addition of 
all salary and hardware costs. Time and cost factors that did not 
differ between the scenarios were ignored, as they did not inﬂ uence 
the ﬁ nal result.  
 Statistical and Ethical Considerations 
 A sample size calculation was performed in order to detect a 
signiﬁ cant reduction in the need for forceps biopsies due to success-
ful ROSE-TBNA. Based on published data and previous experi-
ence, we assumed that malignant disease would be encountered in 
75% of patients. Of these, 40% would be diagnosed on TBNA with 
a 75% success rate of ROSE. Based on these conservative estimates 
a cohort of 85 patients would be necessary for signiﬁ cance in a two-
tailed test of proportions (p  ! 0.05, power 0.8). The institutional 
ethical review board approved the study. All patients gave written 
informed consent. 
 Results 
 Patients, Diagnosis and TBNA 
 Ninety patients (76% male) with a mean age of 57 
years (range: 15–88) underwent FB with ROSE-TBNA 
from September 2001 to February 2003. Seventy patients 
(78%) had malignant disease, 16 (18%) non-malignant 
disease and 4 (4%) remained undiagnosed (table  1 ). Di-
agnoses were established on FB (TBNA: n = 60, other 
modalities: n = 11), on repeat ﬂ exible or rigid bronchos-
copy (n = 3), on sputum (n = 2), on surgical (n = 2) or 
transthoracic biopsy (n = 3), and on clinical grounds and 
observation on follow-up (n = 4). In total, 162 lesions were 
aspirated (mean per patient: 1.8, range: 1–3). These in-
cluded paratracheal tumours and lymph nodes above tra-
cheobronchial level (7%), tracheobronchial lymph node 
stations (68%) and peribronchial, submucosal, endobron-
chial or peripheral lesions below tracheobronchial level 
(25%). The number of ROSE-TBNA performed was 322 
(mean per site: 2.1, range: 1–4; mean per patient: 3.6, 
range: 1–7).  
 Yield and Accuracy of ROSE 
 Overall, TBNA was diagnostic in 60 of 90 FB (67%), 
in 84 of 162 aspirated sites (52%) and in 124 of 322 single 
aspirates (39%). The yield of TBNA was higher in neo-
plastic than in non-neoplastic disease, higher in small-cell 
than in non-small-cell lung cancer and relatively poor in 
left tracheobronchial position (table  2 ). ROSE was posi-
tive for diagnostic material in 59 procedures (66%). Out 
of all positive single aspirates, 84% were detected by 
ROSE. Not detected were 20 positive aspirates from 15 
patients. In 13 of these, however, ROSE identiﬁ ed diag-
 Table 1. Diagnosis and yield of TBNA (n = 90) 
Clinical diagnosis Patients Diagnostic 
TBNA 
Neoplastic disease 70 (78) 55 (79)
Small-cell lung cancer 18 (20) 16 (89)
Non-small-cell lung cancer 49 (54) 36 (73)
Lymphoma 2 (2) 2 (100)
Metastatic tumor 1 (1) 1 (100)
Non-neoplastic disease 16 (18) 4 (25)
Tuberculosis 8 (9) 3 (38)
Sarcoid 3 (3) 11 (1)
Pneumonia 3 (3) 0
Silicosis 2 (2) 0
Undiagnosed 4 (4) 0
All 90 (100) 59 (66)
Values in parenthesis are percent.
1 Non-caseating granuloma recovered with a 21-gauge cytology 
needle. Conﬁ rmed with a 19-gauge histology needle specimen.
 Table 2. Sites and yield of TBNA overall and in patients with neo-
plastic disease 
Aspirated Positive, %
All patients (n = 90) 162 52
Paratracheal node or mass1* 11 45
Tracheobronchial N2 or N3 110 47
Tracheobronchial right 26 54
Tracheobronchial left 15 27
Infra- or precarinal 69 49
N1 location 22 59
Other2 19 89
Patients with neoplastic disease (n = 70) 128 65
Paratracheal node or mass1 9 56
Tracheobronchial N2 or N3 81 60
Tracheobronchial right 22 64
Tracheobronchial left 11 36
Infra- or precarinal 48 65
N1 location 20 60
Other2 18 94
N1, N2, N3 = Lymph node locations according to ATS [19].
1 Above tracheobronchial.
2 Peribronchial, submucosal, endobronchial and peripheral.
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nostic material on at least one other TBNA, so that only 
2 patients with positive TBNA were missed by ROSE and 
underwent additional sampling (ﬁ g.  1 ). On the other 
hand, 2 aspirates from the same patient were false posi-
tive on ROSE, which led to inappropriate termination of 
the sampling process in this patient. The provisional di-
agnosis of non-small-cell lung cancer (NSCLC) was later 
conﬁ rmed with transthoracic CT-guided biopsy. Overall, 
sensitivity and speciﬁ city of ROSE for detection of diag-
nostic material in a patient with positive TBNA were both 
96.7%. Negative and positive predictive values were 93.5 
and 98.3%, respectively. 
 A speciﬁ c provisional diagnosis was made in 31 out 
of 59 positive ROSE procedures: NSCLC subtypes (n = 
19), small-cell lung cancer (SCLC; n = 11) and Hodgkin’s 
lymphoma (n = 1). Among these, two provisional diag-
noses of large cell carcinoma were amended to adeno-
carcinoma on the ﬁ nal diagnosis. Twenty-eight ROSE 
procedures were declared diagnostic pending further 
staining: Undifferentiated malignancy (n = 4), NSCLC 
(n = 15), SCLC or lymphoma (n = 4), granulomatous 
disease (n = 4) and metastatic cancer (n = 1). Except for 
the 1 false-positive case, all these could later be diag-
nosed on TBNA material. No misclassiﬁ cation between 
SCLC and NSCLC occurred with ROSE. In 1 patient, a 
non-caseating granuloma was recovered with a 21-gauge 
TBNA, and sarcoidosis was conﬁ rmed with 19-gauge 
TBNA needle histology specimens recovered in the same 
FB. This procedure was rated ROSE positive for the 
study. 
 Impact of ROSE 
 ROSE detected diagnostic material at the ﬁ rst site 
sampled in 50% of all procedures. Overall, 64% of FB 
could be terminated early because diagnosis and/or stag-
ing had been completed after TBNA. This means that 
sampling methods other than TBNA were only necessary 
in 35% of all FB performed. Moreover, ROSE-TBNA re-
sults assisted in adjusting the sampling strategy in 5 ad-
ditional cases of tuberculosis or sarcoidosis, so that ROSE-
TBNA had an important contribution in 71% of all FB. 
Compared to the alternative scenario without ROSE, the 
necessity to perform a forceps biopsy was signiﬁ cantly 
reduced from 65 to 18% by the employment of ROSE 
 (p  !  0.01,   2  test). 
 Time- and Cost-Effectiveness of ROSE 
 All participants, except the cytopathologist, saved 
time with ROSE (table  3 ). The bronchoscopist and the-
atre nurse saved time due to shorter procedure duration, 
the cytopathology technician prepared and screened few-
er cytology and histology specimens, and less paperwork 
saved administrative cost. On the other hand, the cyto-
pathologist on average spent 17 min more per patient 
with ROSE than for a standard laboratory-based analysis. 
Because the cytopathologist has a relatively high salary, 
the net effect on salary cost was a small loss per ROSE 
procedure (table  4 ). However, the savings for consumable 
tools due to ROSE outweighed the extra salary expense, 
even though we calculated that diagnostic brushes and 
biopsy forceps would be used for 3 and 7 procedures, re-
spectively. This means that ROSE is cost-effective based 
on the infrastructure of our hospital. To adjust for differ-
 Table 3. Time balance for one bronchoscopy with and without 
ROSE 1 
With ROSE
person-min
Without 
ROSE
person-min
ROSE 
balance2
person-min
Bronchoscopist 38 47 –9
Cytopathologist3 44 27 17
Theatre nurse 38 47 –9
Cytology technician 67 74 –7
Administration 8 18 –10
 Rand = currency of South Africa. 
1 Average values from 90 bronchoscopies.
2 Negative ﬁ gures represent savings by ROSE.
3 Includes 12 min for the way to the theatre and back. Fig. 1. Accuracy of ROSE-TBNA performed in 90 ﬂ exible bron-
choscopies. Sensitivity and speciﬁ city of ROSE for detecting a di-
agnostic TBNA in a patient were both 96.7%; negative and positive 
predictive value were 93.5 and 98.3%, respectively. 
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ent local situations, the respective data in table  3 and  4 
can be replaced with the locally valid numbers.  
 Discussion 
 This prospective study found that screening of trans-
bronchial aspirates by a cytopathologist in theatre al-
lowed sampling to be discontinued after aspiration of 
only one site in 50% of cases and in 64% of patients after 
TBNA of multiple sites without requiring other sampling 
modalities. ROSE had a sensitivity of 97% for diagnostic 
material on TBNA. Savings owing to fewer samples sub-
mitted for analysis and reduced use of consumables out-
weighed the cost for the extra service provided by cyto-
pathology. These results were achieved in 90 consecutive 
patients with mixed pathology representative for routine 
practice. 
 Despite the high sensitivity of ROSE in this study, the 
overall yield of TBNA (60%) was lower than that report-
ed by Diette et al.  [16] (81%) and Chin et al.  [17] (71%). 
This is probably due to selection bias, since ROSE was 
not systematically used in these studies. Moreover, the 
present study included a larger proportion of patients 
with non-neoplastic diseases, in which the yield of TBNA 
is lower. For aspirates in tracheobronchial location, how-
ever, the present study achieved 60% diagnostic TBNA 
compared an average yield of 42% in other studies  [1, 2] . 
Besides possible differences in methodology, there are 
several plausible reasons why ROSE can improve the 
yield of TBNA. Firstly, negative or uncertain ﬁ ndings on 
ROSE can be addressed immediately with repeated aspi-
rations of the same site with a slightly modiﬁ ed technique. 
This feedback-guided strategy leads to a variable number 
of aspirates and is indisputably better than sampling an 
arbitrary number of aspirates of uncertain quality  [17] . 
Secondly, the often minute TBNA samples are handled 
and processed in the best possible way with ROSE, which 
is an often overlooked but important factor for good 
TBNA yield  [15] . Thirdly, the availability of ROSE leads 
to a more frequent use of TBNA and hence practical ex-
pertise, which is likely to improve the performance of 
both bronchoscopists and cytopathologists  [11] . Further-
more, ROSE encourages the use of TBNA not only for 
formal staging but also for submucosal, exophytic and 
peripheral lesions, which are known to have a good yield 
with TBNA  [5] . 
 ROSE provides the opportunity to stop sampling when 
the diagnostic objective has been met. To take full advan-
tage of this option means to accept cytological aspirates 
 Table 4. Expenses for one bronchoscopy 
with and without ROSE 1 Cost factor With ROSE Without ROSE Cost
balance2
min, Rand Rand spent Rand spent Rand
Salaries
Bronchoscopist 3.32 126.1 156.0 –29.9
Cytopathologist 4.06 178.6 109.6 69
Theatre nurse 0.9 34.2 42.3 –8.1
Cytology technician 1.4 93.8 103.6 –9.8
Administration 0.4 4.0 7.2 –04
Total salaries 17.2
Unit, Rand Units used Units used Rand
Consumables3
Cytology brush 44 0.18 0.72 –23.8
Biopsy forceps 32 0.2 0.77 –18.2
Total consumables –42
Total cost –24.8
Rand = currency of South Africa. 
1 Average values from 90 bronchoscopies.
2 Negative ﬁ gures represent savings by ROSE.
3 Cost based on one brush being used for 3 and one forceps for 7 procedures, respec-
tively.
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for diagnosis and classiﬁ cation of lung cancer also in pa-
tients with lesions potentially accessible for a forceps bi-
opsy. This is controversial, because it may be argued that 
the diagnostic quality of needle aspirates is inferior to 
histological specimens provided by forceps biopsies. In 
contrast to all other sampling modalities, however, needle 
aspirates can be scrutinized for quality on site. Conse-
quently, the cytopathologist can ask for more aspirates or 
even a forceps biopsy specimen to ensure that the mate-
rial is adequate for all ancillary tests required. It has been 
shown that the concordance of TBNA and forceps biop-
sies is excellent  [5] , and that no single sampling method 
has a superior yield in FB  [4] . It is widely accepted that 
combining conventional sampling methods (bronchial 
washing, brushing and endobronchial biopsy) with TBNA 
increases the yield of FB  [4, 5, 8, 9] . The present study 
shows that the yield of FB can be predicted with high ac-
curacy with ROSE. Multiple sampling methods are there-
fore only necessary in a minority of cases, which are best 
identiﬁ ed by a cytopathologist attending the procedure. 
For further management in bronchogenic carcinoma the 
accurate distinction of SCLC from NSCLC is of utmost 
importance. TBNA is the most sensitive sampling meth-
od for SCLC  [20–23] , while forceps biopsies are prone to 
crush artefacts and sometimes difﬁ cult to interpret  [24] . 
The subclassiﬁ cation of NSCLC is less important for rou-
tine clinical practice and can be challenging on broncho-
scopic specimens in general  [4, 21, 25] .  
 It has been held against ROSE that it is a time-consum-
ing and inadequately remunerated procedure  [4, 15, 16, 
26] . In order to balance personnel and hardware cost in-
volved, we undertook a detailed and comprehensive cost-
effectiveness estimate. Our model showed that ROSE led 
to fewer biopsy tools used and fewer samples submitted 
for the cytology and pathology laboratories. Overall, re-
duced hardware and salary costs compensated for the 
time and cost of the on-site cytopathology service. We 
acknowledge that this analysis is not universally general-
izable and factors such as hospital geography, local health 
care system and available expertise must be accounted 
for elsewhere. However, we believe that the cost of ROSE 
is generally overestimated. The superior access to clinical 
and radiological information in theatre is an advantage 
that might compensate the cytopathologist for the incon-
venience of displacement. Very little has been written 
about the practical aspects of ROSE-TBNA, including 
which method of staining is more effective. The rapid 
Papanicolaou stain used in the present study has superior 
demonstration of nuclear morphology and hence neoplas-
tic characteristics of an aspirate, but it takes 3 min to 
complete. Quicker stains, such as Diff-Quik  [18] , which 
are superior for demonstrating lymphocytes may still be 
evaluated. The type and size of the TBNA needle as well 
as the minimum level of experience of the specialists in-
volved are as yet unknown variables for the yield of 
ROSE-TBNA.  
 EBUS to visualize the target area is a new tool set to 
improve the yield of TBNA  [12, 27] . In addition, EBUS 
demonstrates the ultrastructure of the tracheobronchial 
wall and enables decision making about treatment mo-
dalities of early cancer of the central airways  [13] . Even 
peripheral lesions and solitary pulmonary nodules are in 
reach of EBUS  [28] . However, EBUS is still costly, re-
quires considerable technical skill and is unlikely to be-
come popular outside specialized centres in the near fu-
ture. Interestingly, a study comparing EBUS-guided 
TBNA with conventional TBNA for mediastinal adenop-
athy showed an equally high yield with both methods 
 [12] . ROSE was used for determination of specimen ad-
equacy in that study, and it was speculated that ROSE 
might increase the sensitivity of standard TBNA to the 
same degree as EBUS. However, no studies have yet di-
rectly compared the yield of EBUS-guided and ROSE-as-
sisted TBNA and the respective value of the methods 
needs further investigation.  
 The results of the present study demonstrate that 
ROSE increases the value of TBNA as a diagnostic mo-
dality. In our institution, bronchoscopists and cytopa-
thologists alike have come to appreciate the high yield, 
accuracy and brevity of ROSE-assisted procedures. The 
patients beneﬁ t of a swift procedure and accelerated man-
agement provided by ROSE, which is now requested as 
part of our routine bronchoscopy service for every lesion 
likely to be reached with TBNA. 
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 It Is Time for This ‘ROSE’ to Flower 
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tochemistry or microbiological studies, or to repeat the 
sample using histology needles, if histological material is 
considered useful for perfecting the diagnosis. 
 A ‘ROSE’ is a ﬂ ower, but it is also the acronym fre-
quently employed to indicate Rapid On-Site Evaluation 
of the material obtained by needle aspiration techniques; 
other authors use the less romantic acronym ICA, which 
stands for Immediate Cytological Assessment  [3] . 
 In recent years, in an effort to improve the sensitivity 
and the diagnostic yield of the needle aspiration tech-
niques, new technologies of guidance have been proposed 
(endobronchial ultrasound, virtual bronchoscopy, CT ﬂ u-
oroscopy, 3D navigation systems)  [4–6] , but only few pa-
pers have focused on the role of correct management, 
preparation and examination of the sampled material 
which is an essential point to achieve good results.  
 In 1993, analyzing data from 55 patients who under-
went percutaneous ﬁ ne-needle aspiration from a lung le-
sion suspected for cancer, Austin and Cohen  [7]  obtained 
a sensitivity of 100% in 25 cases performed with ROSE 
and of 80% in 30 cases where the biopsy was performed 
without the cytopathologist. In the same paper, the meta-
analysis of the previously published data showed that the 
immediate cytological assessment was associated with a 
statistically signiﬁ cant increase in diagnostic accuracy 
compared with the procedures performed when a cytopa-
thologist was not present. In 1998, in a series of 207 
TBNA performed on 161 patients, comparing 73 aspi-
rates using ROSE with 134 routinely processed samples, 
Davenport  [8] showed that the percentage of specimens 
containing malignant cells increased from 31 to 56% and 
that the inadequate TBNA decreased from 56 to 18% 
 In the last decades, needle aspiration techniques have 
gained ground in respiratory medicine, especially for the 
diagnosis and staging of lung cancer. Techniques such as 
percutaneous ﬁ ne-needle aspiration and transbronchial 
needle aspiration (TBNA) have been demonstrated to be 
reliable sampling tools in clinical practice. Their use al-
lows cytohistological diagnosis of malignancy and numer-
ous benign conditions with good sensitivity and excellent 
speciﬁ city, avoiding more invasive surgical procedures 
such as mediastinoscopy, video-assisted thoracoscopic 
surgery or thoracotomy  [1, 2] .  
 One of the advantages of the cytological aspiration 
techniques is the possibility to immediately evaluate the 
material with rapid stain methods to deﬁ ne the adequacy 
of the sample and to obtain a preliminary diagnosis, if the 
cytopathologist is present in the diagnostic room. The 
presence of a cytopathologist during the needle aspiration 
procedures also ensures that the material will be treated 
and prepared in the best way. The results obtained by the 
immediate cytological assessment provides the operator 
with invaluable information on how to carry on with the 
procedure that can be stopped if the material is diagnos-
tic, avoiding further and useless passes with the needle, 
thereby reducing time and risks. On the contrary, if the 
sample is not diagnostic, other needle passes can be per-
formed by the operator who, on the basis of the informa-
tion provided by the cytopathologist, could modify the 
technique of sampling or the point of punction. Further-
more, if required by the immediate assessment and 
deemed necessary by the cytopathologist, the operator 
could be invited to sample additional material for ancil-
lary techniques, such as electron microscopy, immunocy-
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when the cytopathologist was present. Likewise, in a pro-
spective cohort study on 204 patients who underwent 
bronchoscopy for evaluation of lung nodules or masses 
and/or hilar and mediastinal lymphadenopathy, Diette et 
al.  [9]  obtained a diagnostic yield of 81% in the 81 cases 
performed with ROSE versus 50% in the cases without 
immediate cytological assessment. 
 Despite this evidence of diagnostic advantages, ROSE 
is still not a very widespread procedure, and in many in-
stitutions, the pulmonologists ﬁ nd several difﬁ culties to 
persuade the cytopathologists to participate directly in 
needle aspiration activities. 
 There are mainly two reasons for these difﬁ culties. 
 The ﬁ rst is due to a lack of pathologists speciﬁ cally 
trained and dedicated to cytology in many institutions. 
Generally, traditional pathologists do not like to leave 
their ofﬁ ces, heading for the diagnostic rooms with a mi-
croscope. They think that this could mean a loss of time, 
taken away from their routine diagnostic activity. Pul-
monologists should use their enthusiasm and make every 
effort to convince the pathologists of the diagnostic efﬁ -
cacy of ROSE, which could be compared in its value with 
the intraoperative frozen section examination activity 
that, on the contrary, is well spread and accepted world-
wide. As underlined by Miller et al.  [10] and as we have 
veriﬁ ed in our experience of more than 20 years  [3] , the 
great educational relevance of ROSE for the staff, arising 
from the opportunity to discuss the cases together at the 
time of the examination, should also be emphasized. 
 The second and possibly main reason why ROSE is 
not very widespread is that its cost effectiveness has not 
yet been demonstrated. Without doubt, the extra time 
and effort of the cytopathologist is a cost that should be 
considered and adequately reimbursed. The inadequate 
economical consideration does not encourage the cytopa-
thologists to participate on site at the diagnostic proce-
dures.  
 In this issue of  Respiration, the paper of Diacon et al. 
 [11] does not only focus on the diagnostic utility of ROSE 
during bronchoscopy using TBNA, but also on the eco-
nomical aspects of the immediate cytological examina-
tion, with an accurate and detailed analysis of the costs 
of the material and the work of all the operators involved 
in the procedure, including physicians, nurses, cytology 
technicians and administrative staff. The costs have been 
calculated for bronchoscopies performed with ROSE and 
for an alternative scenario for sampling without ROSE. 
The results show that all the staff save time with ROSE, 
except for the cytopathologist who on average spends 17 
min more per patient. However, even considering the rel-
atively high salary of the cytopathologist, saving on con-
sumable tools and time of the other operators allowed 
ROSE to save 24.8 rand (the currency of South Africa, 
where the study was performed) per patient. These data 
led the authors to conclude that ROSE is not only highly 
useful in increasing the diagnostic value of the TBNA 
procedures, but also cost effective.  
 As underlined by the same authors in the discussion, 
this conclusion is not universally generalizable and should 
be veriﬁ ed in other countries and other institutions, tak-
ing into account the different organizations of the various 
hospitals and the different costs that material and salaries 
could have. Economic analysis such as that made by Di-
acon et al.  [11] should be encouraged, because if the cost 
effectiveness of ROSE will be universally conﬁ rmed, ev-
ery effort will have to be made to diffuse this practice and 
to stimulate the different health care systems and hospital 
administrations to invest resources in this kind of diag-
nostic approach. 
 I hope that in the future the basic knowledge of cyto-
pathology will be inserted in the training program of pul-
monologists and will become part of their culture and 
qualiﬁ cation. Thus, the presence of a cytopathologist may 
no longer be necessary to perform ROSE. The pulmonolo-
gist could carry out the procedure by himself, further re-
ducing the cost. In many cases, it could be enough to have 
a preliminary evaluation, demonstrating whether neo-
plastic cells are present in the specimen or not. Of course, 
the ﬁ nal diagnosis should remain the task of the patholo-
gist, and nothing would be taken away from his compe-
tence and responsibility. It is incomprehensible why the 
pulmonologist should be able to read and interpret a CT 
scan, when he cannot evaluate, at least preliminarily, a 
cytological slide. Pulmonologists who are able to perform 
ROSE by themselves already exist  [12] , and they receive 
a lot of professional gratiﬁ cation from their practice.  
 At the end of this comment, let me talk about another 
reason that could have stimulated the enthusiasm of Dia-
con et al.  [11] for ROSE. At the last ERS meeting in 
Glasgow, I had the chance to chair a session where a post-
er communication on ROSE was displayed by these au-
thors. The picture showed a cytopathologist performing 
an immediate cytological evaluation on a microscope. Be-
ing used to a cytopathologist with a moustache, it was 
surprising for me to see that a wonderful, blonde woman 
was sitting at the microscope. ROSE is a romantic acro-
nym: if you are lucky to have a nice woman as a cytopa-
thologist, you could have one more reason to hope that 
this ROSE ﬂ owers. 
 
http://scholar.sun.ac.za
 It Is Time for This ‘ROSE’ to Flower  Respiration 2005;72:129–131 131
 References 
 1 Dasgupta A, Mehta AC, Wang KP: Transbron-
chial needle aspiration. Semin Respir Crit Care 
Med 1997;  18:  571–581. 
 2 Mazzone P, Jain P, Arroliga AC, Matthay RA: 
Bronchoscopy and needle biopsy techniques 
for diagnosis and staging of lung cancer. Clin 
Chest Med 2002;  23:  137–158. 
 3 Gasparini S, Ferretti M, Secchi EB, Baldelli S, 
Zuccatosta L, Gusella P: Integration of trans-
bronchial and percutaneous approach in the 
diagnosis of peripheral pulmonary nodules or 
masses. Experience with 1027 consecutive
cases. Chest 1995;  108:  131–137. 
 4 Herth F, Becker HD, Ernst A: Conventional vs 
endobronchial ultrasound-guided transbron-
chial needle aspiration: A randomized trial. 
Chest 2004;  125:  322–325. 
 5 White CS: Transbronchial needle aspiration: 
Guidance with CT ﬂ uoroscopy. Chest 2000; 
 118:  1630–1638. 
 6 Becker HD: Bronchoscopy. Year 2001 and be-
yond. Clin Chest Med 2001;  22: 225–239. 
 7 Austin JHM, Cohen MB: Value of having a 
cytopathologist present during percutaneous 
ﬁ ne-needle aspiration biopsy of lung: Report of 
55 cancer patients and metaanalysis of the lit-
erature. AJR Am J Roentgenol 1993;  160:  175–
177. 
 8 Davenport RD: Rapid on-site evaluation of 
transbronchial aspirates. Chest 1998;  98:  59–
61. 
 9 Diette GB, White P Jr, Terry P, Jenckes M, 
Rosenthal D, Rubin HR: Utility of on-site cy-
topathology assessment for bronchoscopic 
evaluation of lung masses and adenopathy. 
Chest 2000;  117:  1186–1190. 
 10 Miller DA, Carrasco CH, Katz RL, Cramer 
FM, Wallace S, Charnsangavej C: Fine needle 
aspiration biopsy: The role of immediate cyto-
logic assessment. AJR Am J Roentgenol 1986; 
 147:  155–158. 
 11 Diacon AH, Schuurmans MM, Theron J, 
Louw M, Wright CA, Brundyn K, Bolliger CT: 
Utility of rapid on-site evaluation of transbron-
chial needle aspirates. Respiration 2005;
72:182–188. 
 12 Marcianò G, Marino M: Broncologia. En-
doscopia e Citologia. Milano, UTET Ed, 
1993. 
 
http://scholar.sun.ac.za
Appendix E
Transbronchial needle aspirates: comparison of two preparation methods 
Chest 2005;127:2015-8
http://scholar.sun.ac.za
Transbronchial Needle Aspirates*
Comparison of Two Preparation Methods
Andreas H. Diacon, MD; Mace´ M. Schuurmans, MD; Johan Theron, MD;
Karen Brundyn, MD; Mercia Louw, MD; Colleen A. Wright, MD; and
Chris T. Bolliger, MD, PhD
Study objectives: Transbronchial needle aspiration has evolved as a key bronchoscopic sampling
method. Specimen handling and preparation are underrated yet crucial aspects of the technique.
This study was designed to identify which of two widely practiced sample preparation methods
has a higher yield.
Design: Prospective comparison of two diagnostic methods.
Setting: Tertiary academic hospital.
Patients: Consecutive patients undergoing transbronchial needle aspiration.
Interventions: Transbronchial aspirates were obtained pairwise. One specimen was placed
directly onto a slide and smears were prepared on site (ie, the direct technique), and the other
specimen was deposited into a vial containing 95% alcohol and further prepared in the laboratory
(ie, the fluid technique). In total, 282 pairs of samples were aspirated from 145 target sites
(paratracheal, 10 sites; tracheobronchial, 101 sites; hilar, 17 sites; endobronchial or peripheral,
17 sites).
Measurements and results: The measured outcome was the presence of diagnostic material at the
final laboratory assessment. At least one diagnostic aspirate was obtained in 66% of 86
investigated patients (small cell lung cancer, 18 patients; non-small cell lung cancer, 47 patients;
other diagnoses, 21 patients). The direct technique had a better yield overall than the fluid
technique (positive aspirates, 36.2% vs 12.4%, respectively; p < 0.01), as well as after stratifica-
tion for tumor type and for anatomic site.
Conclusion: The direct technique is superior to the fluid technique for the preparation of
transbronchial needle aspirates. (CHEST 2005; 127:2015–2018)
Key words: bronchoscopy; cytodiagnosis; fine-needle biopsy; lung neoplasms
Abbreviations: ATS  American Thoracic Society; TBNA transbronchial needle aspiration
T ransbronchial needle aspiration (TBNA) via flexiblebronchoscopy is an established sampling method
for a variety of lung lesions.1 The most important
indication for TBNA is mediastinal staging of lung
cancer. The lymph node stations that are crucial for
treatment and prognosis, as defined by the TNM
system,2 are easily accessible with TBNA, which is
cost-effective and reduces the need for exploratory
surgery.3 However, the method is still underutilized.4 A
possible reason for this is the failure to reproduce
published success rates of TBNA.5 Investigations1,6
aiming to increase TBNA use and to improve overall
success rates have shown that education and experi-
ence with the TBNA technique improve the yield.
Much less is known about how the samples should be
prepared after successful aspiration. In the original
article by Wang et al,7 the specimens were flushed into
a container and transported as a fluid suspension to the
laboratory, where they were processed further (ie, the
fluid technique).7 Alternatively, the specimen can be
directly placed onto a slide, and immediately smeared
and spray-fixed (ie, the direct technique).8,9 Based on
our own experience, we hypothesized that the direct
technique would be superior to the fluid technique.
This study was designed to clarify whether and to what
degree specimen preparation affects the diagnostic
yield of TBNA in routine practice.
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Materials and Methods
Transbronchial Sampling
Four experienced operators performed standard flexible bron-
choscopy (models BF30 BF1T160; Olympus; Tokyo, Japan;
Exera; Hamburg, Germany) and TBNA under topical anesthesia
(1% lidocaine) and conscious sedation (midazolam IV). TBNA
target sites were defined as (1) paratracheal (lymph nodes or lung
lesions extending to the trachea), (2) tracheobronchial (American
Thoracic Society [ATS] lymph node stations 1 to 410), (3) hilar
(ATS lymph node stations 7 and 11), (4) bronchial (ie, parabron-
chial, submucosal, and endobronchial), and (5) peripheral (ie, not
visible from endobronchial). We used 21-gauge or 22-gauge
cytology needles (Bard; Billerica, MA) and aspirated for 10 s in
the standard fashion.1 Only one needle type was used in a single
patient. A paired sample consisted of two aspirate samples that
were obtained in immediate succession and with identical tech-
nique, with the needle insertion points ideally 1 mm apart. This
assured close proximity of the needle tips during aspiration.
Preparation techniques were alternated after each pass. The
direct technique was used for the first aspirate within a pair when
cytologic support was available on-site. Otherwise, the fluid
technique was used first. The sampling of pairs was completed
without awaiting on-site results. At least four aspirates (two pairs)
at each site were obtained.
Sample Preparation and Analysis
For the direct technique, the aspirate was immediately placed
onto a glass slide, covered with a second slide, and, while exerting
gentle continuous pressure, the slides were drawn apart. One of
the smears was spray-fixed using commercial cytology fixative
(Sangene; Cape Town, South Africa), and the other one was
air-dried. For the fluid technique, the aspirate was deposited into
2 mL 95% alcohol and was processed further in the cytology
laboratory in routine fashion. The fluid was centrifuged at 1,500
revolutions per minute for 10 min, and the resulting sediment
was placed onto two slides, one spray-fixed and the other one
air-dried. All slides were stained using standard Giemsa and rapid
or standard Papanicolau methods.11 Histochemical or immuno-
histochemical examination was performed when necessary on the
destained Papanicolau slides.11 For the study, the test results for
an aspirate were considered to be positive when it contained
diagnostic material (ie, adequate numbers of malignant cells or
distinct features of granulomatous disease with or without necro-
sis). This was determined by two independent cytopathologists,
who were unaware of the preparation method used and of any
provisional diagnoses issued before the final assessment.
Statistical Aspects and Study Progress
The sample size was calculated for the detection of a 10%
difference between the preparation methods assuming a 50%
yield for the better method and an average of four sampled pairs
per patient. A two-tailed test of proportions would show signifi-
cance with 48 patients (power, 0.8; significance level, 95%). The
first analysis showed a surprisingly low yield for the fluid method.
This was thought to probably be due to insufficient material
being expelled into the vials. Subsequently, the fluid method was
modified by using a 50-mL syringe instead of a 20-mL syringe for
aspiration and by expelling the sample with 1 mL of normal saline
solution instead of air. This procedure might lead to better
clearance of aspirated material out of the needle and cannot be
performed with the smear method, because the fluid would wash
the material off the slide. Consequently, separate needles for
each technique were used, which also eliminated the problem of
possible needle contamination with material retained from the
previous pass. The target sample size was doubled in order to
allow for the modifications to show an effect. Counts were
compared with contingency tables and 2 tests (p  0.05 [a
significant difference]) using a statistical software package (Stat-
View, version 4.0 for Macintosh; SAS Institute; Cary, NC). All
patients gave written informed consent. The institutional ethics
review board approved the study.
Results
Patients and Diagnosis
We prospectively included 90 consecutive patients
(56 men) with a mean ( SD) age of 57  15 years
(age range, 16 to 88 years). Of these patients, four
had to be excluded post hoc because faded slide
labels did not allow the identification of the prepa-
ration method that had been used. In the remaining
86 patients, 282 pairs were aspirated from 145 target
sites (paratracheal, 10 sites; tracheobronchial, 101
sites; hilar, 17 sites; bronchial or peripheral, 17 sites).
Two thirds of patients had at least one positive
finding from TBNA. A definitive cytologic diagnosis
with TBNA was possible in more neoplastic than
nonneoplastic lesions (Table 1). Among the neoplas-
tic lesions, small cell lung cancer was more often
identified than non-small cell lung cancer. Among
the nonneoplastic lesions, only one case of sarcoid-
osis and one case of tuberculosis could be identified
with TBNA. The direct method (49 patients; 57%)
was used first more often than the fluid method (37
patients; 43%).
Yield of TBNA and Preparation Methods
The results of at least one TBNA was positive in
112 of 282 pairs of samples (39.7%) collected (Table
2). Only one of the techniques provided a positive
aspirate in 30.8% of pairs (direct technique exclu-
sively positive, 27.3%; fluid technique exclusively
positive, 3.5%). Overall, the direct technique was
Table 1—Patients, Diagnosis, and Yield of TBNA*
Variables Patients, No. Positive TBNA, %
All patients 86 66
Neoplastic disease 68 81
Non-small cell lung cancer 47 77
Small cell lung cancer 18 89
Other neoplastic 3 100
Nonneoplastic disease 18 11
Infectious 9 11
Noninfectious 5 20
Undiagnosed 4 0
*Positive TBNA  at least one aspirate positive for diagnostic mate-
rial.
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significantly superior to the fluid technique (positive
aspirates, 36.2% vs 12.4%, respectively; p 0.01)
[Table 2]. Although differences varied, stratification
for tumor type and for anatomic target site did not
identify a single constellation in which the fluid
technique was superior. The modification of the
fluid technique after 45 patients did not change the
difference between the techniques (before modifica-
tion, 34.8% vs 13%, respectively [p 0.01]; after mod-
ification, 38% vs 11.6%, respectively [p 0.03]).
Discussion
This prospective comparative study showed that
directly prepared and smeared TBNA specimens
provide better results than those expelled into alco-
hol for use in the laboratory. This finding might
contribute to further improve TBNA results and to
promote TBNA as a key technique in bronchoscopic
sampling.
Being situated in the “gray zone” of competence
between bronchoscopist and cytopathologist, the is-
sues of preservation, transport, and preparation of
samples have received very little attention in the
past. The direct smear method was described as an
alternative to the original fluid method soon after the
introduction of TBNA into clinical practice.7–9 To
our knowledge, however, no sufficiently powered
comparative study has compared the methods
against each other, and several review articles1,3,5
have not recommended a specific method for TBNA
specimen preparation. The present study highlights
the importance of the preparation method and its
significant impact on the diagnostic yield of TBNA.
We can only speculate as to the reason for the
superiority of the direct method. Our study used the
patients as their own control subjects, which virtually
eliminated all variables other than the preparation
method. Therefore, the most likely explanation lies
with the loss of cellular material with the fluid
method, which includes initial dilution, centrifuga-
tion, aspiration, and transfer of material onto the
final slides. It seems logical to assume that both the
quality and quantity of a sample may deteriorate with
this multistep approach, even when performed by
trained personnel. In contrast, the direct method
allows the immediate transfer of cellular material
onto slides and results in adequate, well-fixed slides
for cytologic evaluation. A further advantage of
directly smeared slides is their availability for rapid
on-site examination.12
No unequivocal data exist on the absolute yield of
the fluid method. However, its performance in this
study might seem lower than expected in the eyes of
those who routinely use it. One must remember that
in standard clinical practice several successive aspi-
rates are usually flushed into one single vial. This
results in an additive yield of these specimens, while
in the present study single samples were analyzed.
Some shortcomings of the present study must also be
mentioned. First, we employed no objective quanti-
tative and qualitative measures for determining the
slide contents. This means that we cannot prove our
subjective impression that the number of cells avail-
able for analysis is reduced with the fluid method,
while the quality of the cells is well-preserved.
Second, we did not exploit all available variations of
aspiration needle sizes and methods for the prepa-
ration of the fluid specimen. For example, a histo-
logic sample obtained with a larger caliber needle
prepared with the cellblock technique might provide
even better results.13 Third, it might be criticized
Table 2—Yield of Preparation Techniques Stratified for Anatomic Location and Histology*
Variables
Pairs,
No.
Pair,†
% Positive
Direct Method,
% Positive
Fluid Method,
% Positive
p
Value‡
All 282 39.7 36.2 12.4  0.01
Anatomic site
Paratracheal mass or lymph node 25 44.0 44.0 8.0 0.01
Tracheobronchial lymph nodes 206 34.5 32.0 9.7  0.01
Infracarinal or precarinal (ATS 1, 2) 127 34.6 31.5 11.8 0.02
Right (ATS 3) 46 43.5 43.5 8.7 0.02
Left (ATS 4) 33 21.2 18.2 3 NS
Hilar lymph nodes (ATS 7, 11) 22 45.5 31.8 27.3 NS
Peribronchial, submucosal, exophytic, or peripheral 29 69.0 62.1 24.1 NS
Tumor type
Small cell lung cancer 60 55.0 51.7 25.0  0.01
Non-small cell lung cancer 153 45.8 41.2 12.4 0.04
*NS  not significant.
†Pair  either direct method or fluid method, or both, positive for diagnostic material.
‡By 2 test for direct method vs fluid method.
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that we did not randomize the sequence of prepara-
tion techniques used in a paired sample. It is plau-
sible that the second sample could have greater
chances of containing diagnostic material, since
some might have been retained in the needle after
the first pass. However, this would not have changed
the study outcome since second samples were more
often prepared with the fluid method than with the
smear method. Moreover, the use of separate nee-
dles for each technique eliminated this possible bias
in the second half of the study.
TBNA via flexible bronchoscopy is a technically
advanced, minimally invasive, cost-effective, and el-
egant sampling procedure. To achieve a regular high
yield with TBNA, however, careful attention to
technical detail is essential. Smear preparation of a
TBNA sample can be easily learned and will increase
the diagnostic yield of TBNA at very low cost.
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Transbronchial needle aspirates: how many
passes per target site?
A.H. Diacon*, M.M. Schuurmans*, J. Theron*, K. Brundyn#, M. Louw#,
C.A. Wright# and C.T. Bolliger*
ABSTRACT: Transbronchial needle aspiration is a bronchoscopic sampling method for a variety
of bronchial and pulmonary lesions. The present study investigated whether and how serial
needle passes contribute to the yield of transbronchial needle aspiration at specific target sites.
A total of 1,562 needle passes, performed at 374 target sites in 245 patients with neoplastic
disease (82%), non-neoplastic disease (15%) or undiagnosed lesions (3%), were prospectively
recorded and rated for anatomical location, size, bronchoscopic appearance and underlying
disease.
Positive aspirates were obtained in 75% of patients and at 68% of target sites. A diagnosis was
established with the first, second, third and fourth needle pass at 64, 87, 95 and 98% of targets,
respectively. The absolute yield varied strongly with target site features, but the stepwise
increment to the maximum yield provided by serial passes was similar across target sites.
In conclusion, three transbronchial needle passes per site are appropriate when only a tissue
diagnosis is sought and when alternative sites or sampling modalities are available. At least four
or five passes should be carried out at lymph node stations critical for the staging of lung cancer.
KEYWORDS: Bronchoscopy, cytodiagnosis, fine-needle biopsy, lung neoplasms, neoplasm
staging
T
ransbronchial needle aspiration (TBNA)
via flexible bronchoscopy (FB) is a well-
established sampling method for a variety
of bronchial, peribronchial or pulmonary lesions
[1]. Its ability to establish diagnosis and staging in
a single noninvasive intervention has made
TBNA the key technique for the evaluation of
patients with suspected lung cancer [2, 3].
Endobronchial ultrasound (EBUS) [4], computed
tomography (CT) guidance [5] and rapid on-site
evaluation (ROSE) improve TBNA yield [6, 7],
but these methods require considerable resources
and are not universally available. In the absence
of EBUS and/or ROSE, it is common practice to
perform several TBNA passes at a target site to
minimise false-negative results. However, little is
known about the value of serial aspirations. CHIN
et al. [8] reported a plateau in yield after seven
aspirates per patient and per nodal site, while
other authors have reported the performance of
two [9], two to three [10, 11], at least three [12],
three to four [13] or three to five [14, 15] passes
per site. It is well known that TBNA has a higher
yield in neoplastic than in benign lesions, as well
as in small cell lung cancer (SCLC) compared
with nonsmall cell lung cancer (NSCLC) [3, 16].
Other predictors of positive aspirates are greater
size of lymph nodes, infracarinal or right
tracheobronchial position, visible mucosal
abnormalities, such as a widened carina or
erythema, and endobronchial mass lesions [1, 3,
9, 10, 17]. It is unknown whether these para-
meters also predict a higher yield when fewer
aspirates are performed at these sites.
The demonstration of positive N2 or N3 lymph
nodes using TBNA avoids unnecessary surgical
exploration, with its associated morbidity and
cost [3, 18]. Such procedures often require TBNA
sampling of multiple sites, proceeding in a
stepwise fashion from the highest-rated poten-
tially involved nodal site to the primary tumour,
followed by additional sampling modalities.
Patient comfort and safety challenge the bronch-
oscopist to find an optimal compromise between
TBNA yield and (possibly unnecessary) prolonga-
tion of the intervention. The present study inves-
tigated the yield of serial TBNA as a function of
target site characteristics, with the aim of establish-
ing a practical rule for sampling in routine practice.
METHODS
Patients, interventions and diagnoses
All patients undergoing FB with TBNA at the
present authors’ tertiary academic hospital
(Tygerberg Academic Hospital, Cape Town,
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South Africa) from June 2001 to June 2004 were prospectively
recorded. Four chest physicians experienced in TBNA per-
formed all procedures, using standard fibreoptic or video
bronchoscopes (models BF30 and BF1T160; Olympus,
Hamburg, Germany) and standard TBNA for cytological
specimens (Bard, Billerica, MA, USA) under topical anaesthe-
sia (lidocaine 1%) and conscious sedation (midazolam i.v. as
needed). TBNA was always the leading sampling method and
was supplemented at the discretion of the physician with
appropriate additional modalities. For staging of suspected
lung cancer, the potentially highest-rated nodal site was
sampled first. If staging was not of concern, the most
promising site for providing a diagnosis was sampled first.
The final diagnosis was established using the results of the
bronchoscopy or, in cases with negative FB, with appropriate
repeat or additional examinations. All patients signed
informed consent. The study was approved by the institutional
ethical review board.
TBNA and target sites
A target site for TBNA was defined as an area of interest on CT
(anatomical lymph node station or other lesion within reach of
TBNA) or a visible abnormality identified during FB. Target
site features were prospectively recorded. At least five
successive aspirates in close proximity were performed.
Every aspirate was immediately expressed onto a numbered
glass slide and reported separately. TBNA sampling ended
when all target sites had been aspirated or when sufficient
diagnostic material was found with ROSE. ROSE was
performed by a cytopathologist as previously described [7].
The anatomical location of lymph node target sites was
classified according to the American Thoracic Society system
[18] into paratracheal sites above the tracheobronchial level
(stations 2R and 2L), tracheobronchial sites (stations 4R, 4L and
7) and bronchial sites (all sites below tracheobronchial). All
sites were rated for normal or altered appearance (i.e. widened
carina, mucosal infiltration, extrinsic compression). Compres-
sion of a lumen was rated for its degree as partial or complete
(passable with bronchoscope or not) and for appearance
(intrabronchial mass lesion opposed to submucosal or peri-
bronchial disease). Post-bronchoscopy, the sites were further
categorised for underlying disease (neoplastic or benign), type
of lung cancer when applicable (SCLC or NSCLC), and short
axis diameter in the case of tracheobronchial lymph nodes
(assessed on contrasted spiral CT scan with 10-mm sections).
Statistical analysis
It was anticipated that sequential passes at a target site would
result in stepwise yield increments to a plateau. Based on
evidence in a published report [8], it was decided that five
aspirates per site would provide sufficient data points to fit an
exponential function with nonlinear regression (Newton–
Gauss). Every needle pass at a site was reported separately
and entered into a database to provide yields after each
sequential pass. Using these data, separate exponential functions
were created to deduct the yields stratified for target site
characteristics. Proportional data were analysed using a Chi-
squared test of contingency tables or Fisher’s exact test on 262
contingency tables in the case of very small counts (f5).
A p-value ,0.05 was considered significant. Two-sided tests
were used. Data are presented as mean¡SD unless otherwise
stated.
RESULTS
Patients, diagnosis and interventions
A total of 245 patients undergoing flexible bronchoscopy with
TBNA were recorded (age range: 15–88 yrs; median 57 yrs;
66% male). The final diagnosis was neoplastic disease in 200
(82%) and non-neoplastic disease in 36 (15%). Nine (3%)
remained undiagnosed (table 1). Five of these patients died
from clinically advanced malignancy before further investiga-
tions could be undertaken. One patient died undiagnosed from
massive haemoptysis and three were lost to follow-up. TBNA
was diagnostic in 75% of patients overall, in 84% with
neoplastic disease and in 44% with benign lesions.
Target sites
In total, 374 target sites were sampled (1.53¡0.6 per patient)
with 1,562 needle passes (4.2¡1.6 per site; range 1–10). The
site-specific yields are demonstrated in table 2. More than half
of all target sites were at the tracheobronchial level (stations
4R, 4L, 7). Significantly higher yields were seen with increasing
size of lymph nodes and at the tracheobronchial level in right-
sided (station 4R) and infracarinal (station 7) compared to left-
sided (station 4L) lymph nodes. Other statistically significant
predictors of positive aspirates were the presence of a visible
abnormality and neoplastic disease. Among abnormally appear-
ing sites, endobronchial mass lesions were significantly more
often positive than submucosal or peribronchial lesions. Of
borderline significance was the better yield in SCLC compared to
NSCLC. There was no significant difference between partial and
complete endobronchial obstruction.
Sequential yield of TBNA
The cumulative yield obtained from the complete set of 1,562
needle aspirates at 374 sites is displayed in figure 1. The first
TABLE 1 Bronchoscopies, diagnoses and yield of
transbronchial needle aspiration (TBNA)
Underlying
disease
Diagnostic
TBNA#
All 245 (100) 75
Neoplastic disease 200 (82) 84
Nonsmall cell lung cancer 154 (63) 81
Adenocarcinoma 82 (34) 85
Squamous cell carcinoma 25 (10) 84
Undifferentiated carcinoma 47 (19) 72
Small cell lung cancer 39 (16) 95
Other neoplastic" 7 (3) 86
Non-neoplastic disease 36 (15) 44
Sarcoidosis 10 (4) 60
Tuberculosis 14 (6) 71
Other infective lesions 5 (2) 0
Other benign lesions 7 (3) 0
Undiagnosed 9 (3) 0
Data are presented as n (%) or %. #: at least one diagnostic aspirate; ":
metastasis (n54), lymphoma (n52), myeloma (n51).
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needle pass contributed the largest proportion to the total yield
at all sites, and all following passes increased the yield by
,50% of the increase brought about by the previous pass until
a plateau was reached. As expected, this pattern could be
described with a simple nonlinear function. The functions and
graphs established for sites with specific features were very
similar to figure 1 (data not shown; all correlation coefficients
R2.0.96). Table 3 shows the proportional yields of the plateau
yield after the first five sequential passes for each site. The
highest first-pass contribution was achieved at sites with
complete airway obstruction (82.6%) and in endobronchial
mass lesions (76.7%). At all sites, o88% of the plateau yield
was reached with three passes and o94% with four needle
passes.
DISCUSSION
The present study showed that the stepwise increase in TBNA
yield with serial needle passes is similar across target sites
of variable position, aspect, size and underlying disease.
Although the rate of positive TBNA was significantly different
across target sites, the first needle pass consistently contributed
o50% towards the maximum yield, three passes provided 89–
99%, and five passes yielded o98% at all sites. TBNA was
TABLE 2 Target sites and yield of transbronchial needle aspiration
Target sites aspirated Diagnostic# p-value"
All sites 374 (100) 68
Anatomical location+
Paratracheal sites1 32 (9) 75
0.043
,0.001
NSTracheobronchial sitese 212 (57) 56
Bronchial sites 130 (35) 85
Underlying disease
Neoplastic 309 (83) 76
,0.001
Non-neoplastic 55 (15) 35
Bronchial carcinoma
Small cell lung cancer 64 (17) 86
0.052
Nonsmall cell lung cancer 230 (61) 74
Paratracheal and tracheobronchial lymph node sites
Visible abnormality
Present 124 (33) 75
,0.001
Absent 120 (32) 42
Lymph node short axis diameter mm
f10 39 (10) 28
0.004
0.016
,0.00111–20 97 (26) 56
.20 108 (29) 72
Tracheobronchial position
Right## 49 (13) 61
0.004
,0.001
NSLeft"" 34 (9) 29
Subcarinal++ 129 (34) 61
Bronchial sites
Degree of bronchial obstruction
None or partial 70 (19) 80
NS
Complete 60 (16) 92
Bronchoscopic appearance
Peribronchial or submucosal disease 76 (20) 76
,0.001
Endobronchial mass lesion 54 (14) 98
Data are presented as n (%) and %, unless otherwise stated. NS: nonsignificant. #: at least one diagnostic transbronchial needle aspiration per target site. ": Where the
Diagnostic column shows three values consecutively, the figures in left-hand part of the p-value column show a comparison of the first and second and then the second
and third values; values in the right-hand p-value column show a comparison of the first and third values in the Diagnostic column. +: lymph node station according to the
American Thoracic Society system [18]. 1: stations 2R, 2L. e: stations 4R, 4L, 7. ##: station 4R. "": station 4L. ++: station 7.
FIGURE 1. Incremental yield to plateau with sequential needle passes. The
graph describes the yield to plateau in 1,562 transbronchial needle aspiration passes
at 374 target sites. $: measured yield after each sequential needle pass; –––––:
extrapolated yield from an exponential function, obtained by nonlinear regression. The
function is ‘‘yield5100-b06e(b16needle passes)’’, where the coefficients b0 and b1
determine the shape of the curve. The correlation is excellent (R250.999).
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diagnostic in 75% of a large sample of patients representative
for clinical practice.
The ideal number of TBNA passes per target site has not
received much investigative attention in the past. One reason
might be that a negative TBNA result can have a variety of
causes, such as inadequate puncture technique or suboptimal
sample preparation and analysis [17]. Secondly, TBNA has a
sensitivity of only 76–80% in the best hands under study
conditions [10, 19, 20], which means that a negative result is of
limited value even when established with a high number of
aspirates. ROSE by a cytopathologist present in theatre will
effectively optimise the number of aspirates in patients with
positive TBNA but will contribute little when TBNA remains
negative [7, 21]. In contrast, EBUS improves TBNA sensitivity
by assisting the positioning of the needle inside the target
lesion [4]. However, the majority of chest physicians performing
TBNA do not have easy access to EBUS or ROSE and will rely on
their clinical judgement and personal experience to decide on the
number of aspirates in specific bronchoscopic situations.
Tracheobronchial lymph-node sampling for staging of lung
cancer is the best established and most widely used indication
for TBNA. The current results in this subgroup of sites confirm
previous reports that the yield of TBNA is strongly influenced
by the size and location of the targeted lymph node, as well as
by the presence of erythema and a widened carina [3, 16]. Even
though radiological size is a poor predictor for disease in the
mediastinum [22], the current authors’ yield in small nodes
(,10 mm small axis diameter: 29% yield) is surprisingly high.
HARROW et al. [10] reported a TBNA yield in tracheobronchial
lymph nodes ,10 mm of 14% in a large sample of patients
with lung cancer. The explanation for this discrepancy may be
the inclusion of nodes measuring exactly 10 mm into that
group in the present study. The current authors’ yield in nodes
measuring ,10 mm was only 16%. For sites other than
tracheobronchial, the present study confirms the prediction
of positive aspirates by visible abnormalities such as a widened
carina, submucosal infiltration, airway compression or endo-
bronchial mass lesions [9, 16, 17].
TABLE 3 Target sites and yield of sequential needle passes
Yield after needle pass Fit# R2
1 2 3 4 5
All sites 64.5 87.4 95.5 98.4 99.4 0.998
Anatomical location"
Paratracheal sites+ 59.6 83.8 93.5 97.4 99.0 0.996
Tracheobronchial sites1 57.4 82.0 92.4 96.8 98.8 0.997
Bronchial sites 73.5 93.0 98.1 99.5 99.9 0.996
Underlying disease
Neoplastic 64.2 87.2 95.4 98.3 99.4 0.998
Non-neoplastic 68 89.7 96.7 98.9 99.7 0.978
Bronchial carcinoma
Small cell lung cancer 59.5 83.6 93.4 97.3 98.9 0.998
Nonsmall cell lung cancer 65.8 88.3 96.0 98.6 99.5 0.998
Paratracheal and tracheobronchial lymph node sites
Visible abnormality
Present 53.4 78.2 89.8 95.2 97.8 0.991
Absent 60.1 84.2 93.7 97.5 99.0 0.998
Lymph node short axis diameter mm
f10 64.8 87.8 95.8 98.5 99.5 0.968
11–20 59.2 83.2 93.1 97.2 98.8 0.995
.20 51.5 76.7 88.8 94.6 98.8 0.991
Tracheobronchial position
Righte 54.5 79.4 90.7 95.8 98.1 0.995
Left## 60.3 84.3 93.8 97.5 99.0 0.992
Subcarinal"" 57.1 81.7 92.2 96.7 98.6 0.998
Bronchial sites
Degree of bronchial obstruction
None or partial 67.4 89.3 96.5 98.9 99.6 0.997
Complete 82.6 97.0 99.5 99.9 100.0 0.992
Bronchoscopic appearance
Peribronchial or submucosal disease 71.2 91.7 97.6 99.3 99.8 0.996
Endobronchial mass lesion 76.7 94.6 98.7 99.7 99.9 0.996
Data presented as %, unless otherwise stated. #: nonlinear function curve fit (see fig. 1); ": lymph node station according to the American Thoracic Society system [18]; +:
stations 2R, 2L; 1: stations 4R, 4L, 7; e: station 4R; ##: station 4L; "": station 7.
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The good overall yield of 75% in the present study encourages
the use of TBNA regardless of the availability of EBUS support.
While EBUS-guided TBNA is superior in lymph-node targets
,10 mm [23] or in peripheral lung lesions [24], most para-
bronchial lesions can be located using anatomical landmarks,
such as the carina or lobar bifurcations [25, 26]. Moreover,
positive ROSE-TBNA makes EBUS redundant and shortens the
sampling process [7]. The preferred method for mediastinal
staging will not only depend on the available expertise but also
on the prevalence of mediastinal metastases. HOLTY et al. [20]
have recently shown that TBNA has a higher sensitivity in
more advanced mediastinal disease than in situations with
small lymph nodes. This means that non-EBUS-TBNA is
probably sufficient for the majority of patients for whom
confirmation of inoperability is sought. Conversely, EBUS-
TBNA or even surgical staging is best used when a surgically
operable stage is suspected and a high negative predictive
value is important.
In conclusion, what can be recommended for general practice?
Transbronchial needle aspiration is an elegant and effective
technique that takes bronchoscopic sampling beyond visible
abnormalities. Even though other sampling methods are often
equally promising, frequent practice of transbronchial needle
aspiration to hone technical skills is to be encouraged. In
general, it seems reasonable to perform three serial transbron-
chial needle aspiration passes per site when the main objective
is establishing a tissue diagnosis and when alternative target
sites or other sampling modalities are equally promising. Four
or even five transbronchial needle aspiration passes per site
should be carried out if only a single site is available, if
transbronchial needle aspiration is the only potentially
diagnostic sampling method, and if the objective is staging of
lung cancer at critical lymph node stations.
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Ultrasound-assisted transthoracic biopsy:
fine-needle aspiration or cutting-needle
biopsy?
A.H. Diacon*, J. Theron*, P. Schubert#, K. Brundyn#, M. Louw#,
C.A. Wright# and C.T. Bolliger*
ABSTRACT: The present study compared the diagnostic yield of ultrasound-assisted cutting-
needle biopsy (CNB) and fine-needle aspiration biopsy (FNAB) in chest lesions.
A physician performed ultrasound and FNAB with a 22-G spinal needle in all patients, directly
followed by a 14-G CNB in patients without contraindication.
A total of 155 consecutive lesions arising from the lung (74%), pleura (12%), mediastinum (11%)
or chest wall (3%) in patients with a final diagnosis of lung carcinoma (74%), other malignant
tumours (12%), non-neoplastic disease (9%) or unknown (5%) were prospectively included. The
overall diagnostic yield was 87%. Combined specimens were obtained in 123 lesions (79%). In
these, yields of FNAB, CNB and both methods combined were 82, 76 and 89%, respectively. FNAB
was significantly better than CNB in lung carcinoma (95 versus 81%) but CNB was superior in
noncarcinomatous tumours and in benign lesions. On-site cytology was 90% sensitive and 100%
specific for predicting a positive FNAB. One patient required drainage for pneumothorax (0.6%).
Ultrasound-assisted fine-needle aspiration biopsy performed by chest physicians is an
accurate and safe initial diagnostic procedure in patients with a high clinical probability of lung
carcinoma. All other patients should undergo concurrent fine-needle aspiration biopsy and
cutting-needle biopsy.
KEYWORDS: Cutting-needle biopsy, fine-needle aspiration, lung biopsy, lung carcinoma, pleural
biopsy, ultrasound
U
ltrasound (US) has found a firm place in
chest medicine as an aid for assessing
pleural effusions at the bedside [1]. This
development was facilitated by the advent of
affordable, lightweight and mobile US units.
Although less practised by physicians, US can
also visualise solid lesions arising from the
pleura, chest wall and anterior mediastinum,
and even lung tumours and consolidations are
detected without difficulty provided they extend
to the parietal pleura. US is an ideal tool to assist
with biopsy procedures. It can frequently replace
computed tomographic (CT) guidance at much
lower cost [2].
US-assisted cutting-needle biopsy (CNB) per-
formed by chest physicians was 100% sensitive
for mesothelioma in a recent prospective study
carried out at the present authors’ institution [3].
In that study, the majority of candidates for US-
assisted biopsy did not suffer from pleural
disease but presented with peripheral lung
carcinoma, for which fine-needle aspiration
biopsy (FNAB) might be a safer and technically
easier alternative to CNB. US-assisted FNAB
integrates easily with routine practice, as it only
requires basic ultrasound equipment and con-
sumables commonly used by chest physicians for
diagnostic thoracentesis or lymph node aspira-
tion. FNAB and CNB both have a high diagnostic
yield for lung carcinoma under CT guidance [4,
5], which is essential for lung lesions located
within the lung parenchyma. In contrast, US can
only be used on lesions with pleural contact,
which frequently represent rather large and
partly necrotic lung tumours, inflammatory
processes or consolidations due to central bron-
chial obstruction. It is unknown which biopsy
device performs better in chest lesions accessible
to US. The present study directly compared the
diagnostic yield of US-assisted transthoracic
FNAB and CNB.
PATIENTS AND METHODS
All patients referred to the Lung Unit of
Tygerberg Hospital (Cape Town, South Africa;
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tertiary academic centre, catchment area 1.5 million) with
lesions on chest radiography or CT suspected to involve the
chest wall or the pleura were candidates for the present study.
Patients with pleural effusions were not enrolled but were
further evaluated with pleural fluid cytology or thoracoscopy.
A consultant respiratory physician or a registrar under
supervision performed sonography (Toshiba Sonolayer L
SAL 77A, 3.75-MHz sector probe; Toshiba, Johannesburg,
South Africa) and biopsy in free-hand technique (no dedicated
biopsy sonar probe) in a bronchoscopy suite. All patients gave
signed informed consent. Ethical approval from the institu-
tional review board was obtained.
Biopsy procedure
After consulting the radiological evidence the target lesion was
identified with US and the most suitable patient position, as well
as entry site, direction and depth for the biopsy, were
determined. Under local anaesthesia with lidocaine 1%, the
lesion was first aspirated with a 22-G spinal needle (38 or
90 mm; Becton Dickinson, Madrid, Spain) connected to a 10-mL
syringe. Three passes from slightly different areas of the target
were directly expressed onto slides and smeared. The slides
were either air dried or submitted for rapid on-site analysis
(ROSE) using Diff-Quik (Rapidiff; Clinical Sciences Diagnostics,
Southdale, South Africa) or rapid Papanicolaou staining
methods [6]. Immediately thereafter, two or more CNB passes
were performed at the same location until macroscopically
satisfactory material was harvested (14-G cutting needle,
manually driven, specimen notch 20 mm; Allegiance,
Chateaubriand, France). To ensure a consistent effort with the
CNB procedure, the operator was only informed about the
ROSE result upon completion of the CNB. When the lesions
were small (,3 cm in diameter), mobile, in close vicinity to vital
structures, or when a patient was in poor medical condition, it
was left to the physician to decide whether or not to perform a
CNB. The reason for not performing CNB was documented by
the physician. Directly after the procedure, the site was re-
examined with US. A follow-up chest radiograph was obtained
if the pre- and post-biopsy US findings differed and at the
discretion of the physician.
Assessments and measurements
Lesions were classified as follows on radiological appearance
as to the most likely origin: ‘‘pleural’’ (pleural based, blunt
angle to the lung), ‘‘pulmonary’’ (lesion with centre in the
lung, acute angle to the pleura), ‘‘chest wall’’ (lesions centred
in the chest wall with pleural involvement) or ‘‘mediastinal’’
(lesions predominantly located in the anterior mediastinum
with extension to the pleura). The maximum depth of the
target lesion was measured sonographically in the direction of
the planned puncture. If the target extended deeper than
100 mm from the skin, 100 mm was noted. As an indication for
locally advanced disease, the presence of superior vena cava
syndrome or signs of direct spread into nerval tissue (nerve
roots, spinal cord, brachial plexus) was recorded. This would
indicate surgical nonresectability in the setting of nonsmall cell
lung carcinoma.
Scoring and statistical analysis
Specimens with an unequivocal diagnosis of neoplastic disease
or a positive stain or culture for mycobacteria were accepted as
diagnostic. Nondiagnostic specimens contained normal cells or
tissue, nonrepresentative material, or necrotic cells or tissue.
Typing discrepancies between nonsmall cell lung cancer
(NSCLC) subgroups were not considered typing errors
because dual differentiation is common and it is not of
therapeutic relevance. The accuracy of ROSE for predicting
diagnostic material on-site was established by comparison
with the final FNAB result. Patients with nondiagnostic FNAB
and CNB were either clinically observed or further investi-
gated by the appropriate means. Two different pathologists
independently reviewed FNAB and CNB specimens.
Descriptive statistics and Chi-squared comparisons of propor-
tional data were performed. A p-value ,0.05 in a two-tailed
test of proportions (Chi-squared) was considered significant.
RESULTS
Patients and lesions
A total of 155 patients were included over a 23-month period.
Median age was 56 yrs (range 27–90 yrs), 68% were male and
50% were outpatients. The majority of cases were lung lesions
extending to the pleura (n5115, 74%), followed by pleural-
based lesions (n518, 12%), mediastinal lesions (n517, 11%)
and lesions situated in the chest wall (n55, 3%). At the time of
biopsy, a chest radiograph was available in all patients and a
chest CT scan in 100 patients (64%). Locally advanced disease
with clinical signs of superior vena cava compression was
noted in 20 patients (13%) and invasion of spinal or plexus
nerval tissue in 12 (8%). Mean maximum lesion depth from the
skin was 73 mm (range 20–100 mm).
TABLE 1 Diagnosis and yield of fine-needle aspiration
biopsy (FNAB) and cutting-needle biopsy (CNB)
Final
diagnosis
Diagnostic FNAB
and/or CNB
All 155 (100) 135 (87)
Malignant lesions 133 (86) 126 (95)
Lung carcinoma 114 (74) 110 (96)
Small cell carcinoma 11 (7) 11 (100)
Adenocarcinoma 37 (24) 37 (100)
Squamous cell carcinoma 16 (10) 16 (100)
Undifferentiated carcinoma 50 (32) 46 (92)
Sarcoma 8 (5) 8 (100)
Lymphoma 5 (3) 2 (40)
Mesothelioma 2 (1) 2 (100)
Other malignant# 4 (3) 4 (100)
Benign lesions 14 (9) 9 (64)
Fibrosis 6 (4) 2 (33)
Tuberculosis 6 (4) 5 (83)
Lipoma 1 (1) 1 (100)
Wegener’s granulomatosis 1 (1) 1 (100)
Undiagnosed 8 (5)
Data are presented as n (%). #: Thymoma, carcinoid tumour, carcinoma with
unknown primary, prostate cancer.
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Diagnosis, procedures and safety
A final diagnosis was established in 147 patients (95%). Most
diagnoses were established with US-assisted CNB and/or
FNAB (135 patients, 87%; table 1). Twelve patients (8%) were
diagnosed by other means and eight patients (5%) remained
undiagnosed (table 2). The physician decided not to perform
CNB in 32 patients (21%) because of technical or patient-
related reasons (table 3). The diagnostic yield in these patients
was 81% (malignant lesions 92%; benign lesions 57%). Adverse
events did not occur in patients undergoing FNAB only, and
were infrequent and mostly minor in those with combined
procedures. Pneumothorax was observed in two patients
(1.3%), and in one of these, a chest drain was required
(0.6%). Mild puncture-site bleeding (n54, 2.6%), post-proce-
dural pain requiring medication (n52, 1.3%), vagovasal
reaction (n52, 1.3%) and transient mild haemoptysis (n51,
0.6%) were minor events.
Histological diagnosis and correlation in paired samples
Paired diagnostic specimens (FNAB and CNB) were obtained
in 123 patients (79%) with a combined diagnostic yield of
89% (table 4). The yield of FNAB and CNB alone was 82 and
76%, respectively (difference not significant). FNAB had a
significantly higher yield than CNB in neoplastic disease (91
versus 82%, p50.05), mainly due to a higher yield in lung
carcinoma (95 versus 81%, p50.006). Only one case of lung
carcinoma (1%) was identified exclusively by CNB, whereas 14
cases (15%) were diagnosed with FNAB but not with CNB.
Most of these tumours were of larger size than average and all
showed necrosis on histology and/or necrotic areas on CT.
Cytology and histology were concordant for SCLC and NSCLC
in 74 out of 75 cases (99%). One case diagnosed as adeno-
carcinoma on cytology was classified as an atypical carcinoid
on histology with immunohistochemistry, and this was later
confirmed on resection of the tumour. This change in final
diagnosis did not affect the management in that particular
patient as surgical resection was the therapy of choice for both
tumour types. When a diagnosis other than lung carcinoma
was established (n522), CNB was superior to FNAB with 18
versus 12 positive cases (82 versus 55%, p50.056). However, in
eight out of 12 cases with positive FNAB the definite classi-
fication was only possible with the additional information
TABLE 2 Cases with negative biopsy procedures
Description Cases n
Diagnosis established with other means 12
Fibrosis, confirmed with follow-up and full clinical recovery 4
Lymphoma, surgical biopsy 3
Undifferentiated nonsmall cell lung carcinoma, diagnosed with transbronchial
needle aspiration
2
Undifferentiated nonsmall cell lung carcinoma, diagnosed with repeat FNAB/
CNB
2
Full recovery on antituberculous treatment 1
Undiagnosed 8
Deceased from widely metastatic tumour from unknown primary. Patients
wanted no further diagnostic procedures
5
Deceased with metastatic adenocarcinoma of the colon 1
Patient died from HIV-related illness. Aspirated material showed giant cells
and granuloma. Culture for Mycobacterium tuberculosis remained negative
1
Large paravertebral mass. Multiple biopsies revealed necrotic material. Lost
to follow-up
1
FNAB: fine-needle aspiration biopsy; CNB: cutting-needle biopsy.
TABLE 3 Reasons for not performing cutting needle biopsy in 32 patients
Description Patients n
Lesion ,30 mm and/or mobile beyond puncture site 11
Poor general medical condition with impaired cooperation 10
Lesion too close to vital structures 5
Abundant subcutaneous vascularisation in SVC obstruction syndrome 2
Inability to pass biopsy device between ribs 2
FNAB harvested fluid sample only, not suitable for biopsy 2
SVC: superior vena cava; FNAB: fine-needle aspiration biopsy.
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from the CNB specimen (sarcoma n54; lymphoma n52;
mesothelioma n51; thymoma n51). ROSE was 90% sensitive
and 100% specific for predicting the presence of diagnostic
material in positive FNAB.
DISCUSSION
The main finding of this prospective comparison of US-
assisted FNAB and CNB in 155 chest lesions of mixed origin is
the high combined diagnostic yield (87%), with a low rate of
complications. FNAB and CNB are complementary techniques.
Out of all the malignant tumours, 18% were diagnosed with
only one modality. The yield of FNAB alone was significantly
higher in lung carcinoma, while CNB was superior in all other
malignant tumours or in benign diseases. The high yield (95%)
of US-assisted FNAB in 89 cases of lung carcinoma is clinically
relevant. Chest pain indicating pleural involvement is a
common presenting symptom of lung caranoma, and a
considerable proportion of these patients might qualify for
US-assisted FNAB. This procedure is safe, can be performed at
the bedside by a chest physician using the same tools as for a
pleural tap or a diagnostic lymph node aspiration, and might
be preferable to the more expensive and less convenient CT-
guided approach in many cases.
Compared with the current authors’ previous series of 91 US-
assisted CNB [3], the high diagnostic yield has been main-
tained with a reduced pneumothorax rate. This is most
probably due to the fact that FNAB replaced CNB in situations
deemed by the investigator to carry an elevated risk for
pneumothorax. It is reasonable to assume that FNAB causes
less tissue damage than CNB and is therefore an inherently
safer procedure. Small lesions, particularly when mobile on
respiration (fig. 1), are at risk of being punctured slightly off
centre. The chance of causing pneumothorax by accidental
puncture of aerated tissue increases with the size of the biopsy
device. Its safety, combined with its superior yield in lung
carcinoma, makes US-assisted FNAB the first choice for biopsy
of lesions originating from the lung. In contrast, lesions arising
from the chest wall, pleura or mediastinum are, by their
nature, safe targets for CNB because they are not mobile on
respiration and are not surrounded by lung tissue. Such lesions
are also less likely to represent carcinomatous tumours, which
favour CNB due to the better yield in comparison to FNAB. As
an added advantage, FNAB specimens are suited for ROSE,
which is of proven value in transbronchial needle aspiration [7,
8], as well as in CT-guided aspiration of chest lesions [9, 10].
The sensitivity of ROSE for the presence of diagnostic material
was 90% in the present study.
The superior yield of FNAB in lung carcinoma in the present
study is intriguing. FNAB did not have a better yield than CNB
in lung carcinomas in the large series by GONG et al. [4]
reporting on CT-guided biopsies. This may partly be due to
selection bias, because GONG et al. [4] only performed CNB
when FNAB smears were considered suboptimal on immedi-
ate on-site assessment. Another explanation for the high rate of
false-negative CNB could lie in the nature of neoplastic lung
lesions detectable on US. Such lesions often show a non-
homogenous picture with a mixture of necrotic areas, vital
tumour and atelectatic lung tissue. A CNB pass can harvest
a sizeable specimen from one area of the lesion, but this
might only contain nonrepresentative material [5]. Moreover,
scarce vital tumour tissue might easily be missed because
only a small portion of a histological sample can routinely
be cut and analysed under the microscope. In contrast, a
fine needle passed through a lesion repeatedly can sample a
TABLE 4 Diagnostic yield of fine-needle aspiration biopsy (FNAB) and cutting-needle biopsy (CNB) in paired samples
Procedures FNAB and CNB FNAB alone CNB alone Chi-squared#
Total 123 109 (89) 101 (82) 94 (76) NS
Neoplastic lesions 109 104 (95) 99 (91) 89 (82) 0.050
Lung carcinoma 94 91 (97) 89 (95) 76 (81) 0.006
Small cell lung carcinoma 8 8 (100) 7 (88) 7 (88) NS
Nonsmall cell lung carcinoma 86 83 (97) 82 (95) 69 (80) 0.004
Neoplastic other than lung
carcinoma 15
13 (87) 10 (67) 13 (87)
NS
Sarcoma 6 6 (100) 4 (67) 6 (100) ND
Lymphoma 4 2 (50) 2 (50) 2 (50) ND
Mesothelioma 2 2 (100) 1 (50) 2 (100) ND
Other" 3 3 (100) 3 (100) 3 (100) ND
Benign lesions 7 5 (71) 2 (29) 5 (71) NS
Fibrosis 4 2 (50) 0 (0) 2 (50) ND
Tuberculosis, lipoma 2 2 (100) 2 (100) 2 (100) ND
Wegener’s granulomatosis 1 1 (100) 0 (0) 1 (100) ND
All other than lung carcinoma 22 18 (82) 12 (55) 18 (82) 0.056
Undiagnosed 7
Data are present as n and n (%), unless otherwise stated. ND: not done. NS: nonsignificant. #: Chi-squared, FNAB versus CNB; p-values f0.1 are displayed, others are
NS; ": Thymoma, carcinoma with unknown primary, carcinoid tumour (diagnosed as adenocarcinoma on FNAB).
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comparatively large area. The specimen is less voluminous and
can be completely scrutinised after direct transfer onto slides.
This makes a positive result possible even when few vital cells
have been collected. Tissue quality could also explain why
CNB has a higher yield in nonepithelial malignant neoplasms.
These tend to be homogenous and their high intercellular
adherence makes aspiration difficult [4]. CNB specimens also
facilitate the assessment of histological architecture and the
performance of ancillary studies, which is often essential for
classifying such tumours [4].
Despite similarly high yields, ultrasound-assisted fine-needle
aspiration biopsy and cutting-needle biopsy are complemen-
tary methods for establishing a tissue diagnosis in patients
with chest tumours involving the pleura. Considering its low
degree of invasiveness, its simplicity, safety and low cost,
ultrasound-assisted fine-needle aspiration biopsy is the
method of choice in all patients with a high clinical probability
of lung carcinoma. All other patients should undergo
concurrent ultrasound-assisted fine-needle aspiration biopsy
and cutting-needle biopsy.
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FIGURE 1. a) Sonographic image and b) computed tomography (CT) of a subpleural pulmonary tumour (40630 mm on CT) that showed marked movement on
respiration. The small area of contact with the pleura made its location with ultrasound (US) difficult. This patient only underwent fine-needle aspiration biopsy (FNAB). The
diagnosis was adenocarcinoma. c) Sonographic image and d) CT of a lesion of similar size (40630 mm on CT), arising from the lung and adherent to the pleura. The lesion
showed no movement on respiration and the area of contact with the pleura was comparatively large. This lesion was easy to locate with US. This patient underwent FNAB
and cutting biopsy without complications. The diagnosis was large cell lung carcinoma on both specimens.
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Introduction
Rapid on-site analysis (ROSE) improves yield and practical use of transbronchial needle 
aspiration (TBNA). This study compared two on-site staining strategies: 1) “Budget”, a 
simple, 30-second, cytoplasmatic stain (Diff-Quik) carried out and read by one person, and 2) 
“Luxury”, a sophisticated, 3-minute stain with better resolution of nuclear features (Rapid 
Papanicoleau), operated and read by two persons.
Method
We randomised 126 patients (55±15 years; 60% male) to TBNA with budget ROSE (B-
ROSE, n=63) or luxury ROSE (L-ROSE, n=63). Sampling at a target site was terminated 
after 5 passes or upon two positive needle passes. ROSE results were compared to the final 
TBNA laboratory report.
Results
TBNA was positive in 99 (79%) of all patients. With 827 needle passes at 217 target sites we 
diagnosed lung carcinoma (81%), granulomatous disease (17%) and lymphoma (2%). False 
negative and false positive needle passes were more frequent with B-ROSE than with L-
ROSE (27.2% vs 15.1%, p=0.01; 9.6% vs 5%, p=0.18), as well as false negative target sites 
(B-ROSE: 16.9%, L-ROSE 4.5%, p=0.02). No false positive sites occurred with either 
method. B-ROSE resulted in fewer bronchoscopies with positive ROSE (93% vs 100%, 
p=0.20). 
Conclusion
Rapid Papanicoleau is superior to Diff-Quik for yield and accuracy of ROSE-TBNA.
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